

International Conference of the
**Modernization of
Chinese Medicine &
Health Products**

國際現代化中醫藥及
健康產品會議

13-15/8/2026



Organiser 主辦機構

Leading Collaborating Organisation 主要合作機構



Collaborating Organisations 合作機構



一帶一路中醫藥發展聯盟
The Belt and Road Alliance
for Traditional Medicine



國際藥學會有限公司
International Association
of Materia Medica Limited

**International Conference of the
Modernization of
Chinese Medicine & Health Products
(ICMCM) 2026
國際現代化中醫藥及健康產品會議 2026**

Welcome Message

Welcome to the 25th International Conference on the Modernization of Chinese Medicine and Health Products (ICMCM). On behalf of Modernized Chinese Medicine International Association (MCMIA), I would like to express our warmest welcome and sincere thanks to all of you.

Chinese medicine has a long history and rich heritage. It is a valuable asset of the Chinese people. Promoting its innovation, modernization, and global reach is an important goal today. For 25 years, ICMCM has provided an international platform to connect industry, academia, research, and clinical practice, and to advance the globalization of traditional medicine.

This conference is funded by the Chinese Medicine Development Fund of the Hong Kong SAR Government. We thank the Hong Kong Trade Development Council, leading collaborating organization and ten co-organisers for their continued support. The theme this year is clinical translation, Regulatory Policies, and Global Innovative Pathways of the Traditional Medicine. We have gathered top experts to discuss Regulations and standards for traditional medicines, clinical research, Commercialization of CM Research and cultivation of CM Talent.

The 22nd International Postgraduate Symposium on Chinese Medicine, to be held on the third day of the conference, will showcase nearly 100 cutting-edge research outputs from more than 17 universities both in China and abroad. Among these, 10 outstanding postgraduate students from Hong Kong, Macao, Mainland China, Australia, Singapore, South Korea, Vietnam, Serbia, and other countries and regions will deliver oral presentations; over 90 research papers will be presented in poster format."

In parallel with the main programme, this year's conference features newly added Chinese Medicine Educational Display and Public Forum on Chinese medicine to promote wellness and preventive care, and to enhance public's understanding of Chinese medicine.

We hope this conference will build consensus, spark new ideas, and drive progress together.

Wishing you all a successful conference!



Lawrence Lo

President

Modernized Chinese Medicine International Association (MCMIA)

歡迎辭


熱烈歡迎各位蒞臨第二十五屆國際現代化中醫藥及健康產品會議（ICMCM）！我謹代表現代化中醫藥國際協會，向所有海內外嘉賓、專家學者及業界同仁，致以熱烈歡迎與衷心感謝！

中醫藥源遠流長、底蘊深厚，是中華民族的寶貴財富。推動中醫藥守正創新、現代化與國際化，是當下的重要發展方向。二十五年來，ICMCM持續搭建國際交流平台，推動中醫藥產學研醫融合、科研轉化與標準化建設，助力傳統醫藥走向世界。

本屆會議由香港特區政府中醫藥發展基金資助舉辦，感謝主要合作機構香港貿發局及其他十個合作機構長期支持。大會以傳統醫藥臨床轉化、監管政策與國際創新發展為主題，匯聚海內外權威專家，圍繞政策法規、臨床研究、成果轉化、人才培育等議題展開深度研討。會議第三天舉行之「第二十二屆國際研究生中醫藥研討會」將展示超過17所國內外高校的近100項前沿研究成果。其中，來自香港、澳門、中國大陸、澳洲、新加坡、南韓、越南及塞爾維亞等國家及地區的10位優秀研究生將作口頭專題學術報告；逾90篇研究論文將以海報形式展示。

本屆同步增設中醫藥公眾教育展示及中醫保健公開論壇，普及養生與治未病理念，提升大眾對中醫藥的科學認知。

期盼本次大會凝聚共識、激發創新、共謀發展。預祝大會圓滿成功，祝各位嘉賓收穫豐碩、滿載而歸！



現代化中醫藥國際協會
會長
魯展雨

Welcome Message

Welcome to the 25th International Conference of the Modernization of Chinese Medicine & Health Products (ICMCM), jointly organised by the Modernized Chinese Medicine International Association (MCMIA), the Hong Kong Trade Development Council and 10 scientific research institutions and industry associations.

To enable the Chinese medicine market to thrive and reach its full potential, with its century-long tradition of quality service rooted locally yet recognised globally, government support remains crucial. Last year, the Hong Kong SAR Government released its first Chinese Medicine Development Blueprint to accelerate industry progress and establish Hong Kong as a vital bridgehead for this high-growth field.

Given that policy support and the business environment are closely intertwined, this year's conference is themed "Clinical Translation, Regulatory Policies and Global Innovative Pathways of Traditional Medicine", covering a broader scope than in previous years. In addition to sharing the latest research and clinical translation achievements in Chinese medicine, discussions will address key areas to enhance market competitiveness, including regulation of Chinese medicine, import and export policies, talent training and essential resources for industry development, along with quality standards and innovative testing methods that drive standardisation and internationalisation.

The conference brings together over 30 speakers from Australia, Canada, the Chinese Mainland, Hong Kong, Indonesia, South Korea, Macao, Malaysia, Singapore, Thailand, and the UK, including government commissioners, researchers, pharmaceutical executives and other industry leaders, to address the industry's challenges and examine emerging trends.

This year, we are honoured to welcome representatives from Thailand, Indonesia and Malaysia to share their local regulations and standards on Chinese medicine. Speakers from Australia and Canada will present their models, experiences and outcomes in practitioner training, enabling Hong Kong professionals to broaden their global vision and seize new opportunities for Chinese medicine to go global.

ICMCM as a professional platform for the sector fosters knowledge exchange and cross-sector collaboration among practitioners, enterprises, researchers and pharmaceutical firms. In doing so, it aligns with the Hong Kong SAR Government's commitment to promoting and expanding the worldwide presence of Chinese medicine as well as supporting the city's integration into the Greater Bay Area's industrial landscape.

I wish you all a fruitful ICMCM.



Sophia Chong

Executive Director

Hong Kong Trade Development Council

歡迎辭

歡迎各位出席由現代化中醫藥國際協會(MCMIA)聯同香港貿易發展局，以及10所科研機構和行業協會攜手舉辦的第25屆「國際現代化中醫藥及健康產品會議」(ICMCM)。

為推動本港中醫中藥市場蓬勃發展及充份發揮潛力，使百多年來中醫藥耕耘積累的優質服務立足香港、享譽全球，政府的支持仍然是至關重要。去年香港特別行政區政府公布首份《中醫藥發展藍圖》，加快推動行業發展，將香港發展成為中醫藥高增長產業的重要樞紐。

政策支持與營商環境環環相扣。今年會議以「傳統醫藥的臨床轉化、監管政策與邁向國際的創新發展」為主題，討論內容較往年更為廣泛。會上除了分享多項最新中醫藥醫療科研與臨床轉化成果及應用，更涵蓋提升市場競爭力的多個核心範疇，包括中藥監管、進出口相關政策、培訓體系、支援行業發展的重要資源，以及推動產業規範化與國際化的中醫藥質量標準和創新檢測方法。

會議雲集超過30位來自澳洲、加拿大、中國內地、香港、印尼、韓國、澳門、馬來西亞、新加坡、泰國及英國的演講嘉賓，涵蓋政府專員、科研學者、藥企高管及行業領袖，共同探討行業挑戰與最新趨勢。今年大會特別邀得來自泰國、印尼及馬來西亞的代表，分享當地中醫藥法規與標準；另有來自澳洲及加拿大的主講嘉賓，分享其地區的中醫人才培訓模式、經驗及成果，讓本地中藥專業人才放眼全球，把握中醫藥「走出去」的新機遇。

國際現代化中醫藥及健康產品會議作為業界的重要專業平台，促進從業員、商界、科研與藥廠之間的知識交流及跨界別的對接合作。這不僅配合香港政府致力推動中醫藥國際化發展的政策方向，亦有助支持香港融入粵港澳大灣區的產業發展。

我祝願各位在會議上收穫豐碩。



香港貿易發展局
總裁
張淑芬

International Conference of the Modernization of Chinese Medicine & Health Products (ICMCM) 2026 國際現代化中醫藥及健康產品會議2026

Clinical Translation, Regulatory Policies and
Global Innovative Pathways of Traditional Medicine
傳統醫藥的臨床轉化、監管政策與邁向國際的創新發展

Date & Time 日期及時間	13 / 8 / 2026 (Thursday星期四) 9:30 – 18:00 14 / 8 / 2026 (Friday星期五) 9:30 – 18:00 15 / 8 / 2026 (Saturday星期六) 9:00 – 13:00
Venue 地點	Room N101, Hong Kong Convention and Exhibition Centre & Online Streaming 香港會議展覽中心會議室 N101 及 線上直播 (Attendees are welcome to participate in either format 歡迎參會人士以親身或線上出席)
Languages 語言	English and Putonghua英語及普通話 (With simultaneous interpretation service 設即時傳譯服務)
CME Credits 註冊中醫進修學分	Day 1 第一天 — 13 / 8 / 2026 (Thursday 星期四)
	Morning Sessions 上午講座 (10:15 – 12:20) Afternoon Sessions 下午講座 (14:00 – 17:20) 合共 5 學分 Total 5 credits
	Day 2 第二天 — 14 / 8 / 2026 (Friday 星期五)
	Morning Sessions 上午講座 (9:30 – 12:25) Afternoon Sessions 下午講座 (14:00 – 17:45) 合共 6 學分 Total 6 credits Participants must attend Day 1 or Day 2 in full to earn 5 or 6 credits in total per day 參加者必須完整出席第一天或第二天研討會，每天可分別獲得 5 或 6 學分。 Click here for details 按此查看詳情
Registration 登記	https://www.hktdc.com/event/icmcm/en

13 / 8 / 2026 (Thursday 星期四)

9:30 - 10:00

Opening Ceremony 開幕典禮

(Tea Reception & Registration starts at 9am 招待茶會及登記於早上 9 時開始)

Session 1: Keynote Speech 第一節：主題演講

Moderators主持人:

- **Prof. XU Hongxi**, Chairman, Belt and Road Alliance for Traditional Medicine; Honorary Dean & Distinguished Professor, Shanghai University of Traditional Chinese Medicine
「一帶一路」中醫藥發展聯盟主席、上海中醫藥大學首席教授、中藥學院名譽院長 **徐宏喜教授**
- **Prof. LI Min**, Dean & Chair Professor, School of Chinese Medicine, Hong Kong Baptist University
香港浸會大學中醫藥學院院長及講座教授 **李敏教授**

10:15 - 10:25	Hong Kong Chinese Medicine Development BluePrint 香港中醫藥發展藍圖 Dr. Vincent CHUNG Chi-ho , Commissioner for Chinese Medicine Development, Chinese Medicine Unit, Health Bureau 醫務衛生局中醫藥處中醫藥發展專員 鍾志豪博士 (Hong Kong)	
10:25 - 10:50	Hong Kong Chinese Medicine Regulation, Registration, and Import & Export Policies 香港中藥監管、註冊及進出口相關政策 Mr. LAW Kwok-wai, Robert , Chief Pharmacist (Chinese Medicine), Chinese Medicine Regulatory Office, Department of Health 衛生署中醫藥規管辦公室總藥劑師(中醫藥) 羅國偉先生 (Hong Kong)	
10:50 - 11:10	To Share Chinese Medicine Quality Standards and Developing Innovative Testing Methods for Chinese Medicines, as well as to Introduce the Hong Kong Chinese Materia Medica Standards (HKCMMS) and Industry Collaboration 分享中藥質量標準和開發創新中藥檢測方法，並介紹《香港中藥材標準》及產業合作 Dr. YEUNG Kin Wai , Senior Chemist, Government Chinese Medicines Testing Institute, Department of Health 衛生署政府中藥檢測中心高級化驗師 楊建偉博士 (Hong Kong)	
11:10 - 11:30	How The Chinese Medicine Hospital of Hong Kong Supports the Development of the Chinese Medicine Sector 香港中醫醫院如何助力中醫藥業界的發展 Prof. BIAN Zhaoxiang , Hospital Chief Executive, The Chinese Medicine Hospital of Hong Kong & Director, Centre for Chinese Herbal Medicine Drug Development, Hong Kong Baptist University 香港中醫醫院醫院行政總監、香港浸會大學中藥創新研發中心主任 卞兆祥教授 (Hong Kong)	
11:30 - 11:55	To Explore the Core Competencies of Chinese Medicines Professionals and Experiences in Building Training Systems, as well as to Promote an International Perspective in the Cultivation of Chinese Medicines Talent 探討中藥專業人才核心能力及建設培訓體系的經驗，推動中藥人才培養國際化視野 Prof. LI Min , Dean and Chair Professor, School of Chinese Medicine, Hong Kong Baptist University 香港浸會大學中醫藥學院院長及講座教授 李敏教授 (Hong Kong)	
11:55 - 12:20	Integrative Chinese Medicine in the UK: Imperatives, Opportunities and Challenges 整合中醫藥學在英國：必要性、機遇與挑戰 Dr. Qihe XU , Director, King's Centre for Integrative Chinese Medicine, King's College London 倫敦國王學院整合中醫藥學中心主任 徐啟河博士 (United Kingdom)	
12:20 - 14:00	Lunch Break 午膳時間	

Remarks: The organiser reserves the right to make changes to the programme without prior notice
 註：主辦機構保留對會議程序調動之權利而不作另行通知

Session 2: International Regulations & Standards for Chinese Medicine / Traditional Medicine

第二節：中醫藥 / 傳統醫藥國際法規與標準

本節目的：讓國內及外地企業了解香港中醫藥法及支援，並提升本地中醫藥企業對海外市場的認知

14:00 - 14:25

Panel Discussion: Key resources provided by the Hong Kong SAR Government to support industry development, including the provision of innovation and technology land resources and incubation programmes, as well as one-stop professional support to assist enterprises.

專題討論：香港政府支援行業發展的重要資源，包括提供創科土地資源與培育計劃、助力企業提供一站式專業支援


Dr. LUI Nga Ping, Cathy, Principal Manager, Invest Hong Kong
投資推廣署首席經理(生命與健康科學) **雷雅萍博士 (Hong Kong)**



Dr. William CHEUNG, Deputy Chief Manager (Life and Health Technology), Office for Attracting Strategic Enterprises (OASES)
引進重點企業辦公室副總監(生命健康科技) **張家進博士 (Hong Kong)**



Ms. Angela YU, Head of HealthTech and TCM, Smart Manufacturing Division, Hong Kong Productivity Council
香港生產力促進局智能製造部健康科技及中醫藥主管 **虞文盈女士 (Hong Kong)**



Ms. Vicky TSE, Head of Life and Health Technology, Hong Kong Science and Technology Parks Corporation (HKSTP)
香港科技園公司生命健康科技總監 **謝麗娟女士**



Moderator of Panel Discussion 專題討論主持：

Mr. Wing Chu, Deputy Director of Research, Hong Kong Trade Development Council
香港貿易發展局研究副總監 **趙永礎先生 (Hong Kong)**



Moderators 主持人：

- Prof. LIN Zhi Xiu**, Director, School of Chinese Medicine, and Director, Hong Kong Institute of Integrative Medicine, Faculty of Medicine, The Chinese University of Hong Kong; the 3rd batch of the National Qi-Huang Scholar; Registered Chinese Medicine Practitioner (HK)
香港中文大學中醫學院院長、香港中西醫結合醫學研究所所長、第三屆「岐黃學者」、香港註冊中醫師 **林志秀教授**
- Prof. WANG Ning**, Associate Professor and Assistant Director (Research), School of Chinese Medicine, The University of Hong Kong
香港大學中醫藥學院副教授、助理院長(研究) **王寧教授**

14:25 - 14:50

To Share Practical Experiences in Regulatory Innovation for Medicinal Products and Medical Devices in the Guangdong -Hong Kong -Macao Greater Bay Area

分享粵港澳大灣區藥品醫療器械監管創新實踐

Ms. LIANG Yun, Deputy Division Director, Administrative Licensing Division, Guangdong Provincial Medical Products Administration (GDMPA)
廣東省藥品監督管理局行政許可處副處長 **梁雲女士 (Chinese Mainland)**



Remarks: The organiser reserves the right to make changes to the programme without prior notice

註：主辦機構保留對會議程序調動之權利而不作另行通知


14:50 - 15:15	To Share the Driving Forces Behind the High-Quality Development of Hong Kong-Made Chinese Medicine Products and Introducing the Industry Funding Provided by the Hong Kong SAR Government 分享香港製造中藥產品高質量發展的推動力，介紹香港特區政府所提供的產業資助 Dr. Jo Cheung, Manager, Research Strategy Development & Application Office at the Greater Bay Area International Clinical Trial Institute (GBAICTI)	
15:15 - 15:40	Wisdom Wired: Reflections and Prospects on the Transformation of ISO/TC249 智慧互聯: ISO/TC249轉型發展思考與展望 Prof. ZHENG Linyun, Executive Vice President of the Shanghai Academy of International Standardization of Traditional Chinese Medicine 上海市中醫藥國際標準化研究院常務副院長 鄭林贊教授(Chinese Mainland)	
15:40 - 16:05	Regulations and Standards for Traditional Medicine in Thailand 泰國傳統醫藥法規與標準 Mr. Thawatchai NAKKARATNIYOM, Senior Professional Level Pharmacist, Head of Pre-marketing Control Group, Herbal Products Division at Thai Food and Drug Administration, Ministry of Public Health, Thailand (Thailand)	
16:05 - 16:30	Tea Break 茶聚	
16:30 - 16:55	Natural Products / Alternative Medicine Registration in Malaysia 馬來西亞天然產品 / 輔助醫藥註冊 Ms. Nurul Anisah Binti Shahri, Principal Assistant Director, Complementary & Alternative Medicine Section, Centre of Product & Cosmetic Evaluation, National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health, Malaysia (Malaysia)	
16:55 - 17:20	Sharing the Regulations and Standards for Traditional Medicine in Indonesia 分享印尼中醫藥 / 傳統醫藥法規與標準 Dr. Wachyudi Muchsin, Special Staff to the Head of the National Agency of Drug and Food Control of the Republic of Indonesia (BPOM RI), Indonesia (Indonesia)	
End of Day 1 Conference 第一天會議結束		

14 / 8 / 2026 (Friday 星期五)

Session 3: Traditional Medicine / Chinese Medical Development and Clinical Research
第三節：傳統醫學 / 中醫科研發展與臨床研究

Moderators主持人:

- **Prof. FENG Yibin**, Co-Director of the HKUMed Centre of Integrative Medicine, The University of Hong Kong
 香港大學李嘉誠醫學院中西醫結合中心 聯合主任 **馮奕斌教授**
- **Prof. WONG Man-sau**, Professor, Department of Food Science and Nutrition and Director of Research Centre for Chinese Medicine Innovation, The Hong Kong Polytechnic University
 香港理工大學食品科學及營養學系教授及中醫藥創新研究中心主任 **黃文秀教授**

9:30 - 9:55	Exploration and Practice in the Research and Development of Chinese Medicine 中藥製劑研發探索與實踐 Prof. ZHANG Zhongde, Deputy President of Guangzhou University of Chinese Medicine & President of Guangdong Provincial Hospital of Chinese Medicine 廣州中醫藥大學副校長、廣東省中醫院院長 張忠德教授 (Chinese Mainland)	
9:55 - 10:20	Natural Product Drug Development and Clinical Research in Korea 韓國天然新藥物開發與臨床研究 Prof. LEE Sanghoon, Dean, International Education Institute of Korean Medicine, Kyung Hee University 慶熙大學國際韓醫學教育院院長 李相勳教授 (South Korea)	
10:20 - 10:45	Clinical Needs in Developing New Chinese Herbal Medicines for TCM-Advantageous Breast Diseases 淺談乳腺優勢病種中藥新藥的研發臨床需求 Prof. PEI Xiaohua, Dean of Changping Hospital Affiliated to Beijing University of Chinese Medicine and Director of the Institute of Traditional Chinese Surgery 北京中醫藥大學附屬昌平醫院院長、中醫外科研究所所長 裴曉華教授 (Chinese Mainland)	
10:45 - 11:10	Triple-Negative Breast Cancer: Traditional Chinese Medicine-Driven Target and Drug Discovery 三陰性乳癌：中藥智慧驅動靶點發現與藥物研發 Prof. ZHANG Ge, Associate Dean of the School of Chinese Medicine at Hong Kong Baptist University & Director of Law Sau Fai Institute For Advancing Translational Medicine In Bone & Joint Diseases 香港浸會大學中醫藥學院副院長、羅守輝骨與關節疾病轉化醫學研究所所長 張戈教授 (Hong Kong)	
11:10 - 11:35	Post-Market Evaluation Of Anti-Obese Effect Of A Panax Notoginseng Health Product 一款三七減肥保健產品的上市後再評價 Prof. WANG Ning, Associate Professor and Assistant Director (Research), School of Chinese Medicine, The University of Hong Kong 香港大學中醫藥學院副教授、助理院長(研究) 王寧教授 (Hong Kong)	
11:35 - 12:00	Exploring the Efficacy and Safety of Novel Chinese Medicine Formula Against Gout: Preclinical and Clinical Studies 新型臨床經驗方治療痛風的臨床前及臨床研究 Prof. XIAN Yanfang Lisa, Assistant Professor, School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong 香港中文大學醫學院中醫學院助理教授 冼彥芳教授 (Hong Kong)	
12:00 - 12:25	Development of an Integrated Traditional Chinese and Western Medicine System for Chest Pain Management and Resuscitation: From Bench to Clinical Application of Suxiao Jiuxin Pill 中西醫結合胸痛與復蘇體系建設 — 速效救心丸的研發到應用 Prof. Chunjie LI, Chief Physician, Tianjin Chest Hospital 天津市胸科醫院主任醫師 李春潔教授 (Chinese Mainland)	
12:25 - 14:00	Lunch Break 午膳時間	

Remarks: The organiser reserves the right to make changes to the programme without prior notice
 註：主辦機構保留對會議程序調動之權利而不作另行通知

Session 4: Successful Cases Sharing

第四節：成功個案分享

Moderators主持人:

- **Mr. Harry YEUNG Kwok Chun**, Chairman, MCMIA Foundation
現代化中醫藥國際基金 主席 **楊國晉先生**
- **Prof. AU Chin Tung, Dawn**, Director of Chinese Medicine & Culture Research Centre, Li Ning Hon Endowed Professor in Chinese Medicine, Department of Food & Health Sciences, Technological & Higher Education Institute of Hong Kong
中國醫藥及文化研究中心總監、香港高等教育科技學院食品及健康科學學系李甯漢中醫藥教授 **區靖彤教授**

14:00 - 14:25	Sharing Valuable Experience on: The Application and Effectiveness of Good Manufacturing Practice (GMP) for Proprietary Chinese Medicines and the Hong Kong Chinese Materia Medica Standards (HKCMMS) in the Industry, as well as International Marketing of Chinese Medicine 分享中成藥生產質量管理規範(GMP)、《港標》在業界應用方案及成效、及中藥國際化市場營銷的寶貴經驗 Dr. Celine CHENG, Chief Compliance & Technology Officer of Jacobson Pharma Corporation Limited 雅各臣科研製藥有限公司首席合規及技術總監 鄭香郡博士 (Hong Kong)	
14:25 - 14:50	Modernization and Internationalization of Traditional Chinese Medicine and Acupuncture Education in North America 北美中醫藥針灸教育的現代化與國際化發展 Prof. David Dong LIU, Professor, School of Health, Wellness and Sciences, Georgian College 加拿大喬治亞應用文理學院健康、福祉與科學系教授 劉東教授 (Canada)	
14:50 - 15:15	Sharing Experiences and Outcomes from Chinese Medicine Practitioner Training in Australia 分享澳大利亞中醫人才培訓經驗及成果 Prof. ZHU Xiaoshu, Co-Director, Australia-China Chinese Medicine Centre, Western Sydney University, Australia 澳大利亞西悉尼大學中澳中醫中心聯席主任 朱小紓教授 (Australia)	
15:15 - 15:40	The Impact of Modern Life Science Development on the Cultivation of Top-Notch Innovative Talents in Chinese Materia Medica 現代生命科學發展對中藥學拔尖創新人才培養的影響 Prof. XU Hongxi, Chairman, Belt and Road Alliance for Traditional Medicine; Honorary Dean & Distinguished Professor, Shanghai University of Traditional Chinese Medicine 「一帶一路」中醫藥發展聯盟主席、上海中醫藥大學首席教授、中藥學院名譽院長 徐宏喜教授 (Chinese Mainland)	
15:40 - 16:05	Exploring the Demand Characteristics for Chinese Medicine Products in Potential Markets such as ASEAN and Belt and Road Initiative Countries 探討東盟、一帶一路沿線等潛力市場對中藥產品的需求特點 Prof. Linda ZHONG, Director, Biomedical Sciences and Chinese Medicine, School of Biological Sciences, Nanyang Technological University, Singapore 新加坡南洋理工大學生物科學學院生物醫學及中醫學主任 鍾麗丹教授 (Singapore)	

Remarks: The organiser reserves the right to make changes to the programme without prior notice

註：主辦機構保留對會議程序調動之權利而不作另行通知

16:05 - 16:30	Genuine Medicine Market Centralized Trading — SC Chinese Medicine Trading Platform 正藥市場·集中市場 — 守創中藥貿易平台 Mr. SU Shutao , General Manager, Guangzhou SC Chinese Medicine Co., Ltd. 廣州守創中藥有限公司（守創中藥貿易平台）總經理 蘇樹濤先生 (Chinese Mainland)	
16:30 - 16:55	Qualification, Registration, Duties, and Responsibilities of Pharmacist Specialised in Traditional Chinese Medicine (TCM) 澳門中藥師專業資格註冊制度及其核心職能 Mr. LAO Chi Chou , Vice Director, Association of Pharmacists of Chinese Medicine of Macao 澳門中藥師學會副會長 劉智祖先生 (Macao)	
16:55 - 17:20	Honor the Virtue of Our Roots. Heal the World of Tomorrow. 傳承同修仁德底蘊 開闢濟世養生全球健康新征程 Mr. YAN Han , Chairman, Beijing Tong Ren Tang Chinese Medicine Company Limited 北京同仁堂國藥有限公司董事長 嚴哈先生 (Chinese Mainland)	
17:20 - 17:45	Rooted in Hong Kong, Reaching Across Borders — A Two-Way Future for TCM 立足香江融通兩地，打造中醫藥雙向發展新格局 Mr. LI Xiusheng , General Manager, Hong Kong Fangsheng Tang Pharmaceutical Co., Limited 香港方盛堂大藥廠有限公司總經理 黎秀盛先生 (Hong Kong)	
End of Day 2 Conference 第二天會議結束		

15 / 8 / 2026 (Saturday 星期六)

Session 5: The 22nd International Postgraduate Symposium on Chinese Medicine
第五節：第22屆國際研究生中醫藥研討會

Co-ordinator 統籌單位: The Chinese University of Hong Kong 香港中文大學

9:15 - 9:30	The 22nd International Postgraduate Symposium on Chinese Medicine Opening Ceremony 第22屆國際研究生中醫藥研討會開幕典禮
9:30 - 9:40	Vincent & Lily Woo Fellowship in Memory of Dr Albert Wong endowed by Vincent & Lily Woo Foundation" Award Presentation Ceremony 吳文政王月娥獎學金紀念黃伯偉博士吳文政王月娥基金會捐資頒獎典禮
9:40 - 10:00	Oral Research Presentations by 2026 Scholarship Awardees 2026 獎學金獲獎者研究口頭報告
10:00 - 11:15	Oral Research Presentations by International Postgraduate Students 國際研究生中醫藥學術口頭報告
11:15 - 11:30	Break & Poster Session 小休及海報展示環節
11:30 - 12:50	Oral Research Presentations by International Postgraduate Students 國際研究生中醫藥學術口頭報告
End of Day 3 Conference 第三天會議結束	

ICMCM 2026 Organising Committee 籌委會

Prof. Clara Bik San LAU, Modernized Chinese Medicine International Association (MCMIA)

現代化中醫藥國際協會 劉碧珊教授

Ms. Denise SUEN, Modernized Chinese Medicine International Association (MCMIA)

現代化中醫藥國際協會 孫亮女士

Mr. Edward YAU, Modernized Chinese Medicine International Association (MCMIA)

現代化中醫藥國際協會 邱福榮先生

Mr. Harry YEUNG Kwok Chun, Modernized Chinese Medicine International Association (MCMIA)

現代化中醫藥國際協會 楊國晉先生

Conference Organising Committee 會議籌備委員會

Co-conference Chairmen 會議聯席主席

Prof. Hongxi XU, Chairman, Belt and Road Alliance for Traditional Medicine; Honorary Dean & Distinguished Professor, Shanghai University of Traditional Chinese Medicine

「一帶一路」中醫藥發展聯盟主席、上海中醫藥大學首席教授、中藥學院名譽院長 徐宏喜教授

Prof. LI Min, Dean & Chair Professor, School of Chinese Medicine, Hong Kong Baptist University

香港浸會大學中醫藥學院院長及講座教授 李敏教授

Prof. FENG Yibin, Co-Director of the HKUMed Centre of Integrative Medicine, The University of Hong Kong

香港大學李嘉誠醫學院中西醫結合中心聯合主任 馮奕斌教授

Committee Members 委員會成員

Prof. HUANG Yu, City University of Hong Kong

香港城市大學 黃聿教授

Prof. LEE Ming-yuen, Simon, The Hong Kong Polytechnic University

香港理工大學 李銘源教授

Prof. Zhixiu LIN, The Chinese University of Hong Kong

香港中文大學 林志秀教授

Prof. Vivian TAAM WONG, JP, Modernized Chinese Medicine International Association (MCMIA)

現代化中醫藥國際協會 黃譚智媛太平紳士

Prof. Karl TSIM, Hong Kong University of Science and Technology

香港科技大學 詹華強教授

Mr. Harry YEUNG, Modernized Chinese Medicine International Association (MCMIA)

現代化中醫藥國際協會 楊國晉先生

(Name listed in alphabetical order 以英文姓氏順序排列)

Organiser 主辦機構

Leading Collaborating Organisation 主要合作機構



Collaborating Organisations 合作機構



一帶一路中醫藥發展聯盟
The Belt and Road Alliance
for Traditional Medicine



國際藥學會有限公司
International Association
of Materia Medica Limited

The project is funded by the Chinese Medicine Development Fund 本項目由中醫藥發展基金資助:



Any opinions, research, findings, conclusions or recommendations expressed in this material/event (or by the grantee) do not reflect the views or opinions of the Government of the Hong Kong Special Administrative Region, the Health Bureau, the Advisory Committee on Chinese Medicine Development Fund, the Implementation Agent of the Chinese Medicine Development Fund or the Hong Kong Productivity Council.

本資料/活動(或由獲資助機構)所表達的任何意見、研究、結果、結論或建議,並不代表香港特別行政區政府、醫務衛生局、中醫藥發展基金諮詢委員會、中醫藥發展基金執行機構或香港生產力促進局的觀點或意見。

Supporting Organisations 支持機構

Association of Hong Kong and Kowloon Practitioners of Chinese Medicine Limited

港九中醫師公會有限公司

Chinese Medicine Merchants Association Limited

香港中藥聯商會有限公司

Chinese Today

今日華人

Consortium for Globalization of Chinese Medicine

中藥全球化聯盟

Federation of Hong Kong Industries

香港工業總會

Good Practice in Traditional Chinese Medicine Research Association

中醫藥規範研究學會

Hong Kong Asia Youth Association

香港亞洲青年協會

Hong Kong Biotechnology Organisation

香港生物科技協會

Hong Kong Chinese Medicine Pharmacists Association

香港中藥藥劑師協會

Hong Kong Chinese Patent Medicine Manufacturers' Association

香港中華製藥總商會

Hong Kong Registered Chinese Medicine Practitioners Association

香港註冊中醫學會

Hong Kong Youth Association of Chinese Medicine

香港青年中醫協會

Kowloon Chamber of Commerce

九龍總商會

Pharmaceutical and Chinese Medicine Professionals Association

中西藥業專業人員協會

The China Hong Kong Economic Trading International Association

中國香港國際經貿合作協會

The Chinese General Chamber of Commerce

香港中華總商會

The Chinese Manufacturers' Association of Hong Kong

香港中華廠商聯合會

The Hong Kong Health Food Association

香港保健食品協會

The Hong Kong Institute of Biotechnology Limited

香港生物科技研究院有限公司

The Hong Kong Medicine Dealers' Guild

香港藥行商會

The Hong Kong Professional Institute of Chinese Medicine Medicated Meal & Food

香港中醫藥膳專業學會

*Listed in Organisations' alphabetical order 排名以機構英文字母為序

Session 1

第一節

Keynote Speech

主題演講

Hong Kong Chinese Medicine Development BluePrint

香港中醫藥發展藍圖

Dr. Vincent CHUNG Chi-ho, Commissioner for
Chinese Medicine Development, Chinese Medicine Unit, Health Bureau
醫務衛生局中醫藥處中醫藥發展專員 鍾志豪博士 (Hong Kong)

Speaker's Biography 講者簡介

Dr. CHUNG Chi Ho, Vincent is currently the Commissioner for Chinese Medicine Development at the Health Bureau of the Government of the Hong Kong Special Administrative Region. He is also a member of the Board of Directors of The Chinese Medicine Hospital of Hong Kong and a registered Chinese medicine practitioner of the Chinese Medicine Council of Hong Kong. With professional backgrounds in Chinese medicine, evidence-based medicine, and public health, he is primarily responsible for coordinating policy formulation and implementation in key areas including Chinese medicine services, Chinese medicine profession, Chinese medicines development, cultural inheritance, and supporting Chinese medicine in “going global.” He is committed to promoting the comprehensive, high-quality, and high-standard development of Chinese medicine in Hong Kong.

鍾志豪博士為現任香港特別行政區政府醫務衛生局中醫藥發展專員，同時為香港中醫醫院董事局成員，香港中醫藥管理委員會註冊中醫師，具備中醫藥、循證醫學及公共衛生專業背景，主要負責統籌中醫藥服務、中醫專業、中藥發展、傳承文化及助力中醫藥「走出去」等關鍵領域的政策制定及推行，致力推動香港中醫藥全方位、高質量及高水平發展。

Hong Kong Chinese Medicine Regulation, Registration, and Import & Export Policies

香港中藥監管、註冊及進出口相關政策

Mr. LAW Kwok-wai, Robert, Chief Pharmacist (Chinese Medicine),
Chinese Medicine Regulatory Office, Department of Health
衛生署中醫藥規管辦公室總藥劑師(中醫藥) 羅國偉先生 (Hong Kong)

Abstract 摘要

This presentation provides a comprehensive overview of the regulation of Chinese medicines in Hong Kong. It covers the robust regulatory framework under the Chinese Medicine Ordinance (Cap. 549), key milestones since 1999, legal definitions of Chinese herbal medicines (Chm) and proprietary Chinese medicines (pCm), and major measures including licensing, import/export controls, pCm registration (with the new tiered assessment mechanism effective 2026), and pharmacovigilance. It highlights the role of the Government Chinese Medicines Testing Institute (GCMTI) and Hong Kong's active collaborations with Mainland China and international partners such as WHO.

是次演講全面介紹香港中藥規管制度。涵蓋《中醫藥條例》(第549章)下的規管架構、1999年以來的重大里程碑、中藥材及中成藥的法律定義，以及主要規管措施，包括牌照制度、進出口管制、中成藥註冊(2026年起推行分級審評機制)及藥物警戒。重點介紹政府中藥檢測中心(GCMTI)的角色，以及香港與內地及世界衛生組織等國際夥伴的合作。

Speaker's Biography 講者簡介

Mr. Robert Law is a seasoned pharmacist with over 30 years of expertise in traditional Chinese medicine regulation. As Chief Pharmacist, he leads a team of 70+ professionals and oversees all regulatory activities for Chinese medicines in Hong Kong, from registration and licensing to pharmacovigilance.

Since its inception, he has spearheaded the Hong Kong Chinese Materia Medica Standards (HKCMMS) project, publishing over 330 monographs, and serves as Chairman of its Scientific Committee. Internationally, he served as Chairman of the Forum for the Harmonization of Herbal Medicines (FHH) (2021–2022), contributed to multiple WHO Consultations, and is a key member of the WHO Collaborating Centre for Traditional Medicine.

He holds pharmacy degrees from the University of Bradford (UK) and The University of Hong Kong.

羅國偉先生是一位資深藥劑師，在中醫藥規管方面擁有超過三十年專業經驗。作為總藥劑師，他領導一支超過70人的專業團隊，全面負責香港中藥的各項規管工作，涵蓋註冊、發牌以至藥物警戒等範疇。

自香港中藥材標準(HKCMMS)計劃成立以來，他一直主導該計劃的推展，至今已出版超過330個中藥材專論，並擔任其科學委員會主席。在國際層面，他曾於2021至2022年出任草藥協調論壇(FHH)主席，多次參與世界衛生組織相關諮詢會議，並為世界衛生組織傳統醫學合作中心的重要成員。

他持有英國布拉德福德大學及香港大學藥劑學學位。

To Share Chinese Medicine Quality Standards and Developing Innovative Testing Methods for Chinese Medicines, as well as to Introduce the Hong Kong Chinese Materia Medica Standards (HKCMMS) and Industry Collaboration

分享中藥質量標準和開發創新中藥檢測方法，並介紹《香港中藥材標準》及產業合作

Dr. YEUNG Kin Wai, Senior Chemist,
Government Chinese Medicines Testing Institute, Department of Health
衛生署政府中藥檢測中心高級化驗師 楊建偉博士 (Hong Kong)

Abstract 摘要

This presentation introduces specific requirements for regulating the Chinese Medicines (CM) in Hong Kong to ensure the safety of consumers. It highlights, with practical examples, how the Government Chinese Medicines Testing Institute (GCMTI) interacts with the local industries to address their technical challenges through innovative testing methods. Besides, attendees will receive updates on the latest progress of the Hong Kong Chinese Materia Medica Standards (HKCMMS).

是次演講將介紹香港中藥監管的具體要求，以確保消費者的安全。演講將透過實例重點闡述政府中藥檢測中心 (GCMTI) 如何與本地產業合作，運用創新檢測方法應對技術挑戰。

此外，與會者將了解香港中藥材標準 (HKCMMS) 的最新進展。

Speaker's Biography 講者簡介

After obtaining his doctoral degree in Analytical Chemistry, Dr. YEUNG joined the Government Laboratory as a Chemist. Over the years of civil service, he has handled chemical testing in an array of aspects such as Chinese medicines, food and environmental samples, providing professional advices on chemical testing to government bureaux and departments including the former Food and Health Bureau, the Food and Environmental Hygiene Department, the Hong Kong Observatory and the Environmental Protection Department. Dr. YEUNG is a Member of the Royal Society of Chemistry, and a Technical Assessor of the Hong Kong Accreditation Service. He is now serving in the Department of Health as a Senior Chemist, heading the Quality Assurance and Quality Management Section in the Government Chinese Medicines Testing Institute.

楊博士在取得分析化學博士學位後即加入政府化驗所任職化驗師。多年來，他曾負責中藥、食物和環境樣品等各範疇的化學檢測工作，並為政府多個決策局及部門(包括前食物及衛生局、食物環境衛生署、香港天文台和環境保護署)提供化學檢測方面的專業意見。楊博士是英國皇家化學學會會員，同時也是香港認可處的技術評審員。他目前在衛生署擔任高級化驗師，在政府中藥檢測中心帶領質量保證及質量管理組的工作。

How The Chinese Medicine Hospital of Hong Kong Supports the Development of the Chinese Medicine Sector

香港中醫醫院如何助力中醫藥業界的發展

Prof. BIAN Zhaoxiang, Hospital Chief Executive, The Chinese Medicine Hospital of Hong Kong & Director, Centre for Chinese Herbal Medicine Drug Development, Hong Kong Baptist University
香港中醫醫院醫院行政總監、香港浸會大學中藥創新研發中心主任 卞兆祥教授 (Hong Kong)

Abstract 摘要

The Chinese Medicine Hospital of Hong Kong (CMHHK), as the first Chinese medicine hospital in Hong Kong and the local flagship institution for the development of Chinese medicine, is entrusted with the important mission of promoting the high-quality development of Chinese medicine. Positioned as a “change driver” with “develop and transfer” at its core mission, CMHHK will not only continue to deepen Chinese medicine services and drive innovative service models, but also facilitate the translation of outcomes into practice. Through service development, education and training of Chinese medicine practitioners and other healthcare professionals, as well as the advancement of relevant Chinese medicine research, CMHHK will translate applicable outcomes to other Chinese medicine service providers. This presentation will share how CMHHK play its role as a “change driver” by advancing service innovation, talent development, and research translation, thereby supporting the development of Chinese medicine services across the sector.

香港中醫醫院作為香港首間中醫醫院及本地中醫藥發展的旗艦機構，肩負推動中醫藥高質量發展的重要使命。醫院作為「轉化者」以「發展—轉移」為核心，一方面會持續深化中醫藥服務，並推動創新服務模式。同時，透過服務開發、教育與培訓中醫醫師及其他醫療專業人員，並開展相關研究，轉化適用的成果至其他中醫藥服務提供者。本演講將分享香港中醫醫院如何發揮「轉化者」角色，促進服務創新、人才發展及科研轉化，以助力業界發展中醫藥服務。

Speaker's Biography 講者簡介

Professor Bian Zhaoxiang is an expert in Chinese Medicine clinical studies, a Chinese Medicine research scientist in the field of gut dysbiosis, and a passionate advocate for the integration of Chinese Medicine into holistic healthcare system.

Professor Bian's academic pursuit at Nanjing University of Chinese Medicine, where he obtained a degree in Chinese Medicine. He then pursued a Master of Philosophy in Chinese Medicine from Beijing University of Chinese Medicine, followed by a Doctor of Philosophy in Integrative Medicine from Guangzhou University of Chinese Medicine.

Since joining Hong Kong Baptist University in 2001, Professor Bian has held various positions, including the Tsang Shiu Tim Endowed Professor in Chinese Medicine Clinical Studies, Director and Chair Professor of the Clinical Division, Director of the Centre for Chinese Herbal Medicine Drug Development, Director of the Chinese EQUATOR Centre, and Director of the Vincent VC Woo Chinese Medicine Clinical Research Institute.

As Hospital Chief Executive of The Chinese Medicine Hospital of Hong Kong, Professor Bian is leading the Core Management Team, healthcare professionals, and all other hospital staff to pursue the hospital's missions and delivering on its service commitments.

卞兆祥教授是中醫藥臨床研究專家、腸道微生態失調領域的中醫藥研究學者，以及把中醫藥與醫療衛生健康管理體系結合的積極倡導者。

卞教授曾就讀於南京中醫藥大學並取得中醫學學士學位，並於北京中醫藥大學取得中醫學碩士學位，其後再於廣州中醫藥大學取得醫學博士（中西醫結合）學位。

自2001年加入香港浸會大學，卞教授出任多個職位，包括曾肇添中醫藥臨床研究教授、臨床部主任及講座教授、中藥創新研發中心主任、EQUATOR 中國中心主任，以及吳文政中醫藥臨床研究所所長。

作為香港中醫醫院的醫院行政總監，卞教授現正帶領核心管理團隊、醫療專家，以及所有其他醫院員工，實踐醫院的使命，及履行服務契約中的承諾。

To Explore the Core Competencies of Chinese Medicines Professionals and Experiences in Building Training Systems, as well as to Promote an International Perspective in the Cultivation of Chinese Medicines Talent

探討中藥專業人才核心能力及建設培訓體系的經驗， 推動中藥人才培養國際化視野

Prof. LI Min, Dean and Chair Professor, School of Chinese Medicine,
Hong Kong Baptist University

香港浸會大學中醫藥學院院長及講座教授 李敏教授 (Hong Kong)

Abstract 摘要

Establishing core competencies is pivotal for advancing quality and standardization in medical education. To equip future Chinese medicines practitioners in Hong Kong for evolving healthcare demands, a localized core competence framework is being developed through a rigorous, consensus-driven research approach that builds upon existing benchmarks and synthesizes multidisciplinary expert insights. This seminar highlights the imperative of competency-based Chinese medicines education, showcases a landmark cross-institutional development project in Hong Kong, and presents its preliminary research findings.

為促進香港中醫發展，三大院校攜手合作，參考國內外中醫藥及其他醫療專業核心能力標準，凝聚專家共識，制定中醫藥核心能力框架，促進中醫藥專業人才培訓。本次演講將闡述「以能力為本」中醫藥培訓的重要性，並分享初步成果。

Speaker's Biography 講者簡介

Professor Li Min is an acclaimed scholar in the treatment of neurodegenerative diseases using Chinese medicine, currently serving as Dean of School of Chinese Medicine (SCM), Hong Kong Baptist University (HKBU). Joining Hong Kong HKBU in 2001, Professor Li currently holds several positions in SCM: Chair Professor of Chinese Medicine, Ma Pak Leung Endowed Professor in Innovative Neuromedicine, Director of Mr. & Mrs. Ko Chi Ming Centre for Parkinson's Disease Research (CPDR), Golden Meditech Centre for NeuroRegeneration Sciences (GCNS) and HKBU Musketeers Foundation Traditional Chinese Medicine Research Institute for Age-related Diseases.

With over 40 years of clinical practice, teaching, and research in Chinese medicine, Professor Li specialises in the pharmacological studies and clinical treatment of neurodegenerative diseases such as Parkinson's disease (PD), Alzheimer's disease (AD) and Amyotrophic Lateral Sclerosis (ALS) with Chinese medicine, as well as new drug development. She was mentored by Professor Deng Tietao, the first cohort of National Master of Traditional Chinese Medicine (TCM), and Professor Xiong Jibai, the third cohort of National Master of TCM. Professor Li was named the First Cohort of National Outstanding Female Chinese Medicine Practitioner in 2007, and received the HKBU President's Award for Outstanding Performance in Teaching in 2013 and 2018, as well as the President's Award for Outstanding Performance in Research Supervision in 2024. She has consistently been ranked among the world's top 2% scientists by Stanford University in recent years.

Professor Li's research team has published about 200 high-level academic papers in international journals, including Nature Communications, Autophagy, Signal Transduction and Targeted Therapy, and Aging Cell. She has led a number of research projects funded by the National Natural Science Foundation of China and the Research Grants Council of Hong Kong. She has authored over 20 academic monographs and holds more than 20 patents from the United States, Europe, and China.

Professor Li's key research area:

- The relationship between autophagy regulation and neurodegenerative diseases such as Parkinson's Disease (PD), Alzheimer's Disease (AD), and Amyotrophic Lateral Sclerosis (ALS).
- The application of Traditional Chinese Medicine (TCM) in the prevention and treatment of neurodegenerative diseases.
- The identification of molecular targets from TCM for novel drug discovery in neurodegeneration.
- Investigating the efficacy and safety of TCM for conditions such as AD and PD, through randomised controlled clinical trials, whilst also exploring the interaction between TCM and Western medicine.

李敏，醫學博士，講座教授，馬百良創新神經藥物教授，博士生、博士後導師，為中醫內科學及中醫藥治療老年神經退行性疾病專家。李教授於2001年加入香港浸會大學，目前擔任中醫藥學院院長、高智明伉儷帕金森症研究中心主任、金衛醫療神經再生研究中心主任以及香港浸會大學同心基金高齡疾病中醫藥研究所主任。

李教授從事中醫臨床、教學和研究工作逾四十年。目前主要從事老年神經退行性疾病(帕金森症、阿爾茨海默病和肌萎縮側索硬化症等)的中醫臨床治療、中藥藥理研究與新藥研發。曾先後師從第一屆國醫大師鄧鐵濤教授和第三屆國醫大師熊繼柏教授。李教授榮獲「全國首屆傑出女中醫師」稱號(2007年)，獲得香港浸會大學傑出教學表現獎(2013年，2018年)及香港浸會大學傑出研究指導獎(2024年)，近年亦位列斯坦福大學全球Top 2%科學家榜單。

李教授的科研團隊發表了包括“Nature Communications”，“Autophagy”，“Signal Transduction and Targeted Therapy”，“Aging Cell”等在內的國際高水平學術研究論文近200篇，主持國家自然科學基金、香港研究資助局研究基金等多項研究課題。出版學術專著20余部，並獲得了超過20項美國、歐洲及中國專利。

李教授的主要研究領域：

- 自噬調控與神經退行性疾病(如帕金森症、阿茲海默症、肌萎縮側索硬化症)的關係。
- 中醫藥在預防及治療神經退行性疾病中的應用。
- 從中醫藥中發現用於治療神經退行性疾病的新藥分子靶點。
- 通過隨機對照臨床試驗，研究中醫藥治療神經退行性疾病(如阿茲海默症、帕金森症)的療效與安全性，並探索中西醫藥物的相互作用。

Integrative Chinese Medicine in the UK: Imperatives, Opportunities and Challenges

整合中醫藥學在英國：必要性、機遇與挑戰

Dr. Qihe XU, Director, King's Centre for Integrative Chinese Medicine,
King's College London
倫敦國王學院整合中醫藥學中心主任 徐啟河博士 (United Kingdom)

Abstract 摘要

The UK's adverse health trajectory, despite world-leading biomedical science, creates an urgent imperative to explore complementary approaches. Using herbal medicine and traditional Chinese medicine as exemplars, we illustrate how resources and wisdom from beyond our shores could inform UK innovation. We recommend that the NHS establish a standing committee to rigorously evaluate pharmacological and non-pharmacological interventions, ensuring evidence standards, pharmacovigilance, and phased implementation. This WHO-aligned strategy offers opportunities to address the UK's health crisis through cross-cultural learning. However, substantial challenges remain –limited funding, training gaps, and regulatory fragmentation –which must be overcome for successful integration.

英國生物醫學領先，但國民健康持續惡化。除內部改革外，向外尋求互補資源與智慧已成必要。本文以草藥和中醫為例，闡述域外資源如何推動英國醫學創新。我們建議NHS設立常設委員會，評估補充干預方法，確保循證標準、藥物警戒與分階段實施。此策契合世衛戰略，有望透過跨文化學習應對健康危機。惟資金、教育及監管等挑戰尚待克服，方能成功整合。

Speaker's Biography 講者簡介

Dr. Qihe Xu is Director of the King's Centre for Integrative Chinese Medicine (King's CICM) initiative at King's College London. He led the EU's FP7 GP-TCM Coordination Action on modernisation of Chinese medicine and serves on multiple international boards (eg, The GP-TCM RA) and editorial roles (eg, Deputy Editor-in-chief, WJTCM). With 36 years of laboratory experience in China, the US and the UK, ten years of clinical practice in China, and over 100 publications, he is an expert in kidney science, herbal pharmacology and integrative medicine. Dr Xu was awarded the 2020 Qihuang International Prize, China Association of Chinese Medicine.

徐啟河博士，倫敦國王學院整合中醫藥學中心主任。主持歐盟FP7 GP-TCM中歐合作項目，任GP-TCM RA理事及《世界中醫藥雜誌》英文刊副主編。擁有中、美、英36年實驗室及10年臨床經驗，主攻腎臟學、藥理學與整合醫學。2020年獲中華中醫藥學會岐黃國際獎。

羅國偉先生是一位經驗豐富的藥劑師，在中藥監管領域擁有超過30年的專業經驗。身為首席藥劑師，他領導著一支由70多名專業人士組成的團隊，負責香港所有中藥監管事務，包括註冊、許可和藥物警戒。

自香港中醫標準(HKCMMS)計畫啟動以來，他一直擔任該計畫的負責人，已出版超過330部專著，並擔任其科學委員會主席。在國際上，他曾擔任中藥協調論壇(FHH)主席(2021-2022)，參與了多項世界衛生組織磋商，並且是世界衛生組織傳統醫學合作中心的重要成員。

他擁有英國布拉德福德大學和香港大學的藥學學位。

Session 2

第二節

International Regulations & Standards for Chinese Medicine / Traditional Medicine 中醫藥 / 傳統醫藥國際法規與標準

Panel Discussion: Key resources provided by the Hong Kong SAR Government to support industry development, including the provision of innovation and technology land resources and incubation programmes, as well as one-stop professional support to assist enterprises

專題討論:香港政府支援行業發展的重要資源，包括提供創科土地資源與培育計劃、助力企業提供一站式專業支援

Speaker's Biography 講者簡介

Dr. LUI Nga Ping, Cathy, Principal Manager, Invest Hong Kong
投資推廣署首席經理(生命與健康科學) 雷雅萍博士(Hong Kong)

Dr. Cathy Lui is currently a Principal Manager (Life and Health Sciences) at Invest Hong Kong.

InvestHK is the HKSAR Government's dedicated investment promotion agency, providing free, confidential and customised support for companies to establish and expand in Hong Kong and to use the city as a platform for outbound investment. It delivers sector-specific advice, coordinates with relevant government bodies and professional service providers, and offers ongoing aftercare to foster sustained inward and outward business growth. InvestHK also works closely with other government departments to reflect investor feedback in policy design, strengthen the overall business environment and enhance Hong Kong's competitiveness as an international investment hub.

雷雅萍博士為現任投資推廣署首席經理(生命與健康科學)。

投資推廣署是香港特別行政區政府轄下專責促進投資的機構，為有意在港設立或擴展的企業提供免費、保密及度身訂造的支援，同時協助企業以香港作為對外投資平台。該署提供行業專屬建議，協調相關政府部門及專業服務機構，並提供持續的跟進服務，以促進雙向投資及業務的持續增長。

Dr. William CHEUNG, Deputy Chief Manager (Life and Health Technology), Office for Attracting Strategic Enterprises (OASES)

引進重點企業辦公室副總監(生命健康科技) 張家進博士(Hong Kong)

Dr. William Cheung is Deputy Chief Manager (Life and Health Technology) at the Office for Attracting Strategic Enterprises (OASES), where he advances Hong Kong's strategic position in biotech and health innovation. With over a decade of industry experience, he previously served as Senior Manager of Business Development at HKSTP, successfully attracting more than 100 biotech companies to Hong Kong. Earlier, he co-founded a clinical laboratory and diagnostics startup, leading R&D on cancer and infectious disease testing. He holds a PhD in Cancer Genetics from The University of Hong Kong and completed postdoctoral training at Yale School of Medicine.

張家進博士現任引進重點企業辦公室生命健康科技副總監，具逾十年業界經驗，致力推動香港生物科技及醫療領域的創新發展。張博士畢業於香港大學，並於耶魯大學完成博士後研究，專注於癌症遺傳學。

Ms. Angela YU, Head of HealthTech and TCM, Smart Manufacturing Division, Hong Kong Productivity Council

香港生產力促進局智能製造部健康科技及中醫藥主管 虞文盈女士 (Hong Kong)

Ms. Angela Yu is currently Head of Healthtech and TCM at the Hong Kong Productivity Council and a member for the Advisory Committee of the Government Chinese Medicines Testing Institute. She has also served on multiple occasions as a judging panel member for City University of Hong Kong's HK Tech 300 and ASGH programmes, and holds two development patents.

She is dedicated to advancing the modernisation of traditional Chinese medicine. She played a key role in designing the Chinese Medicine Development Fund and has driven numerous projects in the health and pharmaceutical industries. She has continuously led the planning of government GMP production centres and supported proprietary Chinese medicine manufacturers in progressing from HKP to HKC registration. Furthermore, she has facilitated local enterprises in product development and manufacturing upgrades, while actively designing and deploying AI-powered solutions into TCM practice, driving ongoing transformation and advancement of the TCM industry.

虞文盈女士，為香港生產力促進局新型工業化部生命健康及中醫主管，香港特別行政區政府中藥檢測中心諮詢委員會委員，亦曾多次擔任香港城市大學HK Tech 300及ASGH評審委員，並獲得兩項開發專利。

她致力推動中醫藥現代化，於設計「中醫藥發展基金」中擔當要角並落實多項健康及藥品行業發展項目，更多次主導規劃政府 GMP 生產中心、協助多間中成藥企業由過渡性註冊轉為正式註冊；同時支援本地企業進行產品開發及生產升級，並將人工智能技術融入全方位中醫診療實務，持續幫助中醫藥產業升級發展。

Ms. Vicky TSE, Head of Life and Health Technology, Hong Kong Science and Technology Parks Corporation (HKSTP)

香港科技園公司生命健康科技總監 謝麗娟女士 (Hong Kong)

Ms. Vicky Tse is the Head of Life and Health Technology in Hong Kong Science and Technology Parks Corporation (HKSTP)

Vicky is a well-versed executive in the Life-Science industry. She served as the General Manager at Sanofi Greater China in Shanghai, where she spearheaded successful launches and market expansion, forged key partnerships, enhancing the patient journey through innovative ecosystem collaborations. Prior to Sanofi, she spent over 13 years in progressive leadership roles at Novartis, most recently as Commercial Director for the Asia Pacific, Middle East, and Africa regions, where she led strategic initiatives that accelerated the launch of innovative portfolio across diverse markets. Her impactful journey at Novartis also included pivotal positions as General Manager and President of Taiwan, as well as senior Head roles across Greater China and Hong Kong, where she excelled in steering strategic portfolio growth and building robust commercial foundations. Vicky's earlier roles included strategy development at various managerial levels within Schering-Plough, Roche, and MSD, where she consistently achieved strong performance, built purposed driven team and clear strategy with good execution and collaboration.

Vicky holds a Bachelor of Science from The University of Hong Kong and a Master of Business Administration from the Hong Kong University of Science and Technology.

謝麗娟女士現任香港科技園公司生命健康科技總監，帶領團隊推動生命與健康科技組合及生態圈的發展，助力園區企業持續取得成功。

謝女士是製藥業界經驗豐富的管理者。她此前在上海擔任賽諾菲大中華區總經理，期間推動產品成功上市，建立關鍵戰略合作，並通過創新生態協作優化患者診療流程。加盟賽諾菲前，她在諾華工作超過13年，逐步晉升至領導層，最後出任亞太、中東及非洲區商務總監，主導多項戰略計畫，加速創新療法在不同市場的落地。在諾華期間，她亦曾擔任臺灣地區總經理兼總裁等重要職務，以及大中華區高級副總裁和香港總經理，擅長推動戰略性產品組合增長及構建穩健的商業基礎。謝女士職業生涯早期，在先靈寶雅、羅氏及默沙東擔任不同管理職務，負責戰略規劃，持續提升銷售業績、打造高效團隊並推動新產品上市。

謝麗娟女士持有香港大學理學學士學位及香港科技大學工商管理碩士學位。

Moderator of Panel Discussion

Mr. Wing Chu, Deputy Director of Research, Hong Kong Trade Development Council
香港貿易發展局研究副總監 趙永礎先生 (Hong Kong)

Wing Chu oversees the activities of all of the HKTDC Research economists, including the dedicated Greater China, Asia and global teams. Together, these units are responsible for monitoring and analysing a broad array of economic and international trade issues, with a particular focus on topics relevant to Hong Kong's trade and business landscape. HKTDC's economists also track developments across the key industry sectors most closely linked to Hong Kong's economic growth, including electronics, technology, and professional services.

Wing Chu's recent research projects included an assessment of the impact of changing US trade policies, an analysis of Chinese Mainland's outbound investment strategy, and a review of the regional e-commerce opportunities. He has also provided an overview of the opportunities arising from the continuing evolution of the Greater Bay Area and is currently conducting an ongoing appraisal of the increasing number of regional free trade agreements. Beyond this, he frequently leads his teams in its collaborations with many of the leading economic institutions in Hong Kong, the Chinese Mainland and overseas as they jointly conduct research projects across a number of priority sectors.

趙永礎目前是香港貿發局的研究副總監，負責領導貿發局經貿研究的經濟師團隊，包括大中華區、亞洲以及全球市場專隊，共同監察及分析廣泛的經濟與國際貿易狀況，特別聚焦與香港商貿有關的議題。經濟師團隊還關注對香港經濟有重大影響的關鍵產業發展趨勢，例如電子產業、科技創新和專業服務等領域。

趙永礎近期的研究領域包括評估美國貿易政策變化的影響、中國對外投資、電子商務、粵港澳大灣區發展及區域自由貿易協定等方面的相關議題。他並且帶領團隊與多家香港、內地及海外機構合作，在選定的經貿領域進行聯合研究項目。

To Share Practical Experiences in Regulatory Innovation for Medicinal Products and Medical Devices in the Guangdong - Hong Kong -Macao Greater Bay Area

分享粵港澳大灣區藥品醫療器械監管創新實踐

Ms. LIANG Yun, Deputy Division Director, Administrative Licensing Division,
Guangdong Provincial Medical Products Administration (GDMPA)
廣東省藥品監督管理局行政許可處副處長 梁雲女士 (Chinese Mainland)

Abstract 摘要

This presentation shares practical experiences in regulatory innovation for medicinal products and medical devices in the Guangdong–Hong Kong–Macao Greater Bay Area. It highlights key policy outcomes, including: the "Hong Kong and Macao Medicament and Medical Device Access" scheme; streamlined approval procedures for over-the-counter proprietary Chinese medicines from Hong Kong and Macao; support for cross-border manufacturing of Hong Kong and Macao proprietary Chinese medicines in the Mainland; advancement of the Greater Bay Area standard system for Chinese medicinal materials; and cross-border utilization of proprietary Chinese medicine preparations from medical institutions.

分享粵港澳大灣區藥品醫療器械監管創新實踐。重點介紹港澳藥械通、推進港澳外用中成藥簡化審批、支持港澳中成藥跨境至內地生產、推動中藥灣區標準建設，以及醫療機構中藥制劑跨境使用等政策成效內容。

Speaker's Biography 講者簡介

Ms. Liang Yun holds a Ph.D. in Social and Administrative Pharmacy from China Pharmaceutical University, serves as a public interest lawyer, and is recognized as a specialized talent in legislative work for Guangdong Province. She currently serves as Deputy Director of the Administrative Licensing Division of the Guangdong Medical Products Administration, where she oversees innovation initiatives regarding medicinal products and medical devices in the Greater Bay Area. She participated in the formulation of the Regulations of Guangdong Province on the Administration of Imported Hong Kong and Macao Medicinal Products and Medical Devices into the Nine Mainland Cities of the Guangdong–Hong Kong–Macao Greater Bay Area.

梁雲，中國藥科大學社會與管理藥學專業博士，公職律師，廣東省立法工作專業人才。現任廣東省藥監局行政許可處副處長，負責大灣區藥品醫療器械創新工作。曾參與制訂《廣東省粵港澳大灣區內地九市進口港澳藥品醫療器械管理條例》。

To Share The Driving Forces Behind The High-Quality Development Of Hong Kong-Made Chinese Medicine Products And Introducing The Industry Funding Provided By The Hong Kong SAR Government

分享香港製造中藥產品高質量發展的推動力， 介紹香港特區政府所提供的產業資助

Dr. Jo Cheung, Manager, Research Strategy Development & Application Office at the Greater Bay Area International Clinical Trial Institute (GBAICTI)

Abstract 摘要

Chinese medicine is popular in Hong Kong. Over the years, Hong Kong has established a comprehensive ecosystem through the registration of Chinese medicine practitioners and proprietary Chinese medicines, university-based professional training, dedicated research and testing facilities, and the establishment of the Chinese Medicine Hospital. Advance in Chinese medicine and practice needs to be underpinned by robust scientific evidence. The Greater Bay Area International Clinical Trial Institute (GBAICTI) strives to promote clinical trials and real-world evidence. GBAICTI is therefore positioned to facilitate evidence generation that would enhance the recognition and adoption of Chinese medicine.

中醫藥在香港深受市民信賴，多年來已建立涵蓋註冊、培訓、科研及醫療服務的完善生態圈。中醫藥的創新發展有賴科學證據支持。粵港澳大灣區國際臨床試驗所致力推動臨床試驗及真實世界研究，為建立中醫藥實證基礎提供重要支撐，提升其認受性及應用。

Speaker's Biography 講者簡介

Dr. Jo Cheung is Manager, Research Strategy Development & Application Office at the Greater Bay Area International Clinical Trial Institute (GBAICTI). She has over 20 years of experience in clinical research, having worked extensively with pharmaceutical sponsors and contract research organisations (CROs).

Wisdom Wired: Reflections and Prospects on the Transformation of ISO / TC249

智慧互聯: ISO/TC249轉型發展思考與展望

Prof. ZHENG Linyun, Executive Vice President of the Shanghai Academy of International Standardization of Traditional Chinese Medicine

上海市中醫藥國際標準化研究院常務副院長 鄭林贊教授 (Chinese Mainland)

Abstract 摘要

This presentation reviews the history of ISO/TC 249 Traditional Medicine and its future strategic roadmap following its title change and expanded scope. It highlights the benefits gained by the consensus-based standards work of Traditional Chinese medicine. It also explores feasible approaches for integrating emerging technologies with international standardization, and puts forward recommendations for the future vision of traditional medicine.

本次報告將分享ISO/TC249 傳統醫藥技術委員會發展歷程及其在更名和擴大範圍後的未來發展規劃。重點介紹中醫藥國際標準化最新成果動向，圍繞智慧互聯數位化發展趨勢，挖掘新一代資訊技術與國際標準體系融合落地可行性，對全球傳統醫藥標準化發展前景作出建議。

Speaker's Biography 講者簡介

- Master of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine
- Master of Public Administration, the Lee Kuan Yew School of Public Policy, National University of Singapore
- Executive Vice President and Secretary-General of the Standardization Committee of the World Federation of Chinese Medicine Societies
- Registered Expert of ISO/TC 249 Traditional Medicine

Prof. Zheng has long been engaged in international education and exchange for traditional Chinese medicine. He is familiar with the current status and global trends of traditional Chinese medicine. He has undertaken and participated in multiple projects of the National Administration of Traditional Chinese Medicine, the World Health Organization. His research areas include global development strategy, international standards, terminology, and translation in the field of traditional Chinese medicine.

- 上海中醫藥大學中醫學碩士
- 新加坡國立大學李光耀公共政策學院公共管理碩士
- 世界中醫藥協會聯合會標準化委員會常務副會長兼秘書長
- ISO/TC 249傳統醫藥技術委員會 註冊專家

長期從事中醫藥國際教育和交流，熟悉中醫藥國際發展現狀和趨勢。承擔和參與了國家中醫藥管理局、世界衛生組織等多項國際化和標準化的項目。研究領域包括中醫藥國際化發展戰略研究、中醫藥國際標準、術語、翻譯。

Regulations and Standards for Traditional Medicine in Thailand

泰國傳統醫藥法規與標準

Mr. Thawatchai NAKKARATNIYOM, Senior Professional Level Pharmacist, Head of
Pre-marketing Control Group, Herbal Products Division at Thai Food and Drug
Administration, Ministry of Public Health, Thailand (Thailand)

Abstract 摘要

The Herbal Products Act, B.E. 2562 (2019), establishes the legal definition of herbal products in Thailand. Under this legislation, products are categorized according to risk management frameworks. This classification system includes Traditional Herbal Medicines, which utilize historical knowledge for therapeutic indications without requiring modern clinical efficacy studies if existing evidence is sufficient. Additionally, the Notification of the Herbal Products Committee dictates the regulatory standards for testing and compliance. This notification specifies the mandatory quality control methods, product specifications, and the analytical testing criteria required to obtain a Certificate of Analysis.

《草藥產品法》(佛歷2562年，即2019年)確立了泰國草藥產品的法律定義。根據該法，產品依照風險管理架構進行分類。此分類體系包括傳統草藥，這類草藥利用歷史知識進行治療，如果現有證據充足，則無需進行現代臨床療效研究。此外，《草藥產品委員會通知》規定了檢測和合規的監管標準。該通知明確了強制性的品質控制方法、產品規格以及獲得分析證書所需的分析檢測標準。

Speaker's Biography 講者簡介

Thawatchai Nakkaratniyom serves as a Senior Professional Level Pharmacist within the Herbal Products Division of the Thai Food and Drug Administration. Professional responsibilities involve regulatory science, policy development, and the standardization of herbal products. Academic credentials include a Master of Science in Drug Development Science from King's College London. Currently, doctoral studies are being pursued as a Ph.D. candidate at the Faculty of Pharmacy, Thammasat University. Research interests focus on pharmacovigilance and risk management, particularly the application of machine learning methodologies to enhance safety monitoring and regulatory frameworks for herbal products.

Thawatchai Nakkaratniyom現任泰國食品藥品監督管理局草藥產品部門高級專業藥劑師。其專業職責包括草藥產品的監管科學、政策制定和標準化。她擁有倫敦國王學院藥物開發科學碩士學位。目前，她正在泰國國立法政大學藥學院攻讀博士學位。她的研究方向為藥物警戒和風險管理，特別關注如何應用機器學習方法來加強草藥產品的安全性監測和監管框架。

Natural Products / Alternative Medicine Registration in Malaysia 馬來西亞天然產品 / 輔助醫藥註冊

Ms. Nurul Anisah Binti Shahri, Principal Assistant Director, Complementary & Alternative Medicine Section, Centre of Product & Cosmetic Evaluation, National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health, Malaysia (Malaysia)

Abstract 摘要

Natural Product Registration in Malaysia The regulation of pharmaceutical, traditional, natural and health supplement products in Malaysia is governed by the Drug Control Authority (DCA). The National Pharmaceutical Regulatory Agency (NPRA) acts as the secretariat to the DCA. Under the Control of Drugs and Cosmetics Regulations 1984 (CDCR 1984), mandatory product registration is required to ensure that all health formulations commercially manufactured, imported, or sold within the market strictly adhere to statutory standards of quality, safety, and efficacy. This presentation delineates the updated regulatory pathways for natural product registration in Malaysia.

Speaker's Biography 講者簡介

Nurul Anisah Shahri is a Senior Assistant Director at the National Pharmaceutical Regulatory Agency (NPRA), Malaysia, with over a decade of experience in pharmacy practice and regulatory affairs. She previously served as a pharmacist at Hospital Putrajaya and Bandar Mas Health Clinic, where she provided pharmaceutical care, medication management, and patient counselling. She now specializes in the evaluation and regulation of traditional medicine products, ensuring their quality, safety, and compliance with national standards. She holds a Bachelor in Pharmacy, BPharm (Hons) from the International Islamic University Malaysia (IIUM), Malaysia.

Sharing the Regulations and Standards for Traditional Medicine in Indonesia

分享印尼中醫藥/傳統醫藥法規與標準

Dr. Wachyudi Muchsin, Special Staff to the Head of the National Agency of Drug and Food Control of the Republic of Indonesia (BPOM RI), Indonesia

Speaker's Biography

Dr. Wachyudi Muchsin, S.H., M.Kes. dr. Wachyudi Muchsin, S.H., M.Kes. is an Indonesian medical doctor, public health professional, and legal practitioner with extensive experience in public health, government relations, strategic communications, and institutional partnerships. He holds degrees in Medicine and Law, as well as a Master's Degree in Health from the Muslim University of Indonesia (UMI), Makassar. Over the past decade, he has held several strategic leadership positions across the healthcare, academic, and public sectors. Since 2016, he has served as Director of the Advanced Medicine Indonesia–America Clinic, overseeing healthcare development and international medical collaboration. From 2017 to 2018, he was Head of the Non-Medical Division at UIT Hospital Makassar, where he managed hospital operations and administrative services. Since 2020, he has been serving as Head of Public Relations and Cooperation at Universitas Islam Makassar, leading institutional partnerships, public relations, and collaborative initiatives. In September 2024, he was appointed as Special Staff to the Head of the National Agency of Drug and Food Control of the Republic of Indonesia (BPOM RI), where he supports strategic initiatives related to national food and drug regulation, stakeholder engagement, and public policy. In addition to his professional career, Dr. Wachyudi is actively involved in various professional and community organizations, contributing to education, healthcare, and public development initiatives across Indonesia.

Session 3

第三節

Traditional Medicine / Chinese Medical Development and Clinical Research

傳統醫學 / 中醫科研發展與臨床研究

Exploration and Practice in the Research and Development of Chinese Medicine

中藥製劑研發探索與

Prof. ZHANG Zhongde, Deputy President of Guangzhou University of Chinese Medicine & President of Guangdong Provincial Hospital of Chinese Medicine
廣州中醫藥大學副校長、廣東省中醫院院長 張忠德教授 (Chinese Mainland)

Abstract 摘要

This presentation explores the development and practice of Chinese medicine formulations. It introduces an integrated R&D system based on clinical resources and physicians' empirical prescriptions, covering prescription optimization, process development, and quality evaluation. Through successful cases such as Wenyang Jiedu Granules and other hospital formulations, the presentation highlights pathways from hospital preparation development to new drug approval and technology transfer. It also discusses current challenges and future strategies, including quality control improvement, mechanism studies, multidisciplinary collaboration, and innovative approaches for the modernization and global development of Chinese medicine formulations.

本報告圍繞中藥製劑研發探索與實踐，介紹醫療機構依託臨床資源和名醫經驗方，構建“處方篩選—工藝優化—品質評價”一體化研發體系的實踐經驗。通過溫陽解毒顆粒、銀翹透邪解毒顆粒等案例，展示院內製劑向中藥新藥及成果轉化的發展路徑，並探討品質控制、機制研究及創新研發模式等未來挑戰。

Speaker's Biography 講者簡介

Zhongde ZHANG, National Renowned Chinese Medicine Doctor, Distinguished Professor under the "Cheungkong Scholars Programme", Qihuang Scholar, Recipient of Special Government Allowance from the State Council, Vice President of Guangzhou University of Chinese Medicine, President of Guangdong Provincial Hospital of Chinese Medicine. Academically, he has put forward core theoretical systems including the Theory of Warming Yang and Detoxifying and the Theory of Regulating Five Zang-Organs in Equilibrium.

張忠德是全國知名的中醫專家，長江學者特派員，齊黃學者，國務院特聘專家，廣州中醫藥大學副校長，廣東省中醫院院長。他的學術研究提出了「溫陽解毒」、「調理五臟」等核心理論體系。

Natural Product Drug Development and Clinical Research in Korea

韓國天然新藥物開發與臨床研究

Prof. LEE Sanghoon, Dean, International Education Institute of Korean Medicine,
Kyung Hee University
慶熙大學國際韓醫學教育院院長 李相勳教授 (South Korea)

Abstract 摘要

The global herbal medicine market, projected to reach \$550 billion by 2030, is driving the transformation of traditional remedies into evidence-based, regulatory-compliant therapeutics. Since 2000, South Korea has advanced natural-product drug development through successive national Promotion Plans and a strong ICH-GCP-aligned clinical-trial infrastructure. In selected cases, prior human-use and safety evidence may support Phase 1 omission, facilitating more efficient development. Korea has consistently ranked among the world's leading clinical-trial countries. Current policy emphasizes multi-component, multi-target evaluation, mechanism-based research, and global clinical development, supporting sustained commercial products such as Joins, Motilitone, and Synatura. Future China–Korea collaboration could integrate China's extensive traditional medicine resources with Korea's clinical-trial infrastructure, advancing evidence-based natural-product therapeutics in global healthcare innovation.

全球草藥市場預計於2030年將達5500億美元，此趨勢正推動傳統療法轉型為具循證基礎且符合法規的治療藥物。自2000年以來，韓國透過一系列國家級推動計劃，以及符合ICH-GCP標準的完善臨床試驗基礎設施，大力推進天然產物藥物開發。在特定情況下，既有的人用經驗及安全性證據可支持豁免第一期臨床試驗，從而促進更高效率的開發流程。韓國持續位居全球領先的臨床試驗國家之列。現行政策強調多成分、多靶點評估、機制導向研究以及全球臨床開發，並支持如Joins、Motilitone及Synatura等持續商業化的產品。未來中韓合作有望將中國豐富的傳統醫學資源與韓國的臨床試驗基礎設施相結合，以推動循證天然新藥開發在全球醫療創新中的發展。

Speaker's Biography 講者簡介

Dr. Sanghoon Lee is a professor at the College of Korean Medicine, Kyung Hee University, specializing in acupuncture and integrative medicine. He serves as the Dean of the International Education Institute of Korean Medicine and as Deputy Director of the East-West Medical Research Institute, which is recognized as a WHO Collaboration Center for Traditional Medicine. Through these leadership positions, he actively promotes the integration of traditional medicine within modern healthcare systems. Dr. Lee's career includes extensive international experience, having studied and worked at renowned institutions such as Johns Hopkins and UC Irvine, which have provided him with a valuable global perspective. His research interests include modernizing acupuncture, developing innovative neo-acupuncture devices, and exploring digital healthcare applications to enhance traditional practices. Dr. Lee's work is focused on promoting a holistic approach to patient care that bridges traditional and contemporary medical practices, offering more integrative healthcare solutions.

李相勳博士現任慶熙大學韓醫學院教授，專攻針灸學與整合醫學領域。他同時擔任韓醫學國際教育學院院長，以及世界衛生組織傳統醫學合作中心認證的東西醫學研究所副所長。透過這些領導職位，他積極推動傳統醫學與現代醫療體系的整合。李博士具有豐富的國際經驗，曾於約翰霍普金斯大學和加州大學爾灣分校等知名學府研修與工作，培養出寶貴的全球視野。其研究重點包括針灸現代化、開發創新針灸裝置，以及探索提升傳統療法的數位醫療應用。李博士致力於推動融合傳統與現代醫學的整體醫療模式，為患者提供更全面的整合醫療解決方案。

Clinical Needs in Developing New Chinese Herbal Medicines for TCM-Advantageous Breast Diseases

淺談乳腺優勢病種中藥新藥的研發臨床需求

Prof. PEI Xiaohua, Dean of Changping Hospital Affiliated to Beijing University of Chinese Medicine and Director of the Institute of Traditional Chinese Surgery
北京中醫藥大學附屬昌平醫院院長、中醫外科研究所所長 裴曉華教授 (Chinese Mainland)

Abstract 摘要

The presentation focuses on the clinical needs for the development of new traditional Chinese medicine (TCM) drugs for dominant breast diseases. It introduces the policy background of TCM review and approval reforms, as well as the integration of human-use experience with evidence-based medicine. Using the compound formula Shaogan Sanyong for the treatment of lactation mastitis and the Fangxia Dihuang formula for intervening in psychosomatic symptoms of breast cancer as case examples, the presentation demonstrates the innovative pathways for TCM drug development that are grounded in clinical value and real-world data. Finally, it offers perspectives on the future directions and prospects for TCM surgical pharmaceutical research and development in the field of Chinese surgery.

演講內容圍繞乳腺優勢病種中藥新藥研發的臨床需求，介紹中藥審評改革、人用經驗與循證融合的政策背景，並以芍甘散癰複方治療哺乳期乳腺炎、防夏地黃方干預乳腺癌心身症狀為案例，展示基於臨床價值與真實世界數據的中藥創新路徑，並展望中醫外科中藥研發方向與前景。

Speaker's Biography 講者簡介

- President, Changping Hospital Affiliated with Beijing University of Chinese Medicine
- Recipient of the Special Government Allowance of the State Council
- Chairman, Surgery Branch of the China Association of Chinese Medicine
- Chairman, Professional Committee for Carbuncle and Gangrene Disorders (Juzheng), World Federation of Chinese Medicine Societies
- Instructor, Seventh Batch of the National Academic Experience Inheritance Program for Prominent TCM Experts
- Instructor, Sixth Batch of the Beijing-Level Academic Experience Inheritance Program for Prominent TCM Experts
- Instructor, Fourth Batch of the Fujian-Level Academic Experience Inheritance Program for Prominent TCM Experts
- Discipline Academic Leader, State Key TCM Discipline of Chinese Breast Disease
- Head, Surgery Department – a Superior Specialty designated by the National Administration of Traditional Chinese Medicine (NATCM)
- Head, General Surgery Department – a National and Beijing-Level Flagship Department of Integrated Chinese and Western Medicine
- Director, Surgical Quality Control Center of the Beijing Administration of Traditional Chinese Medicine
- Chair, Clinical Department of Surgery of Chinese Medicine, Beijing University of Chinese Medicine
- Director, Institute of Surgery of Chinese Medicine
- Member, National Technical Committee for Standardization of Traditional Chinese Medicine (SAC/TC 478), Standardization Administration of China
- Expert, TCM Standards Advisory Expert Pool, National Administration of Traditional Chinese Medicine (NATCM)
- 北京中醫藥大學附屬昌平醫院院長
- 中華中醫藥學會外科分會主任委員
- 第七批全國老中醫藥專家學術經驗繼承工作指導老師
- 福建省第四批老中醫藥專家學術經驗繼承工作指導老師
- 國家中醫藥管理局優勢專科-外科負責人
- 北京中醫藥管理局外科品管中心主任
- 北京中醫藥大學中醫外科研究所所長
- 國家中醫藥管理局-中醫藥標準諮詢專家庫專家
- 享受國務院特殊津貼專家
- 世界中醫藥學會聯合會疽證專業委員會會長
- 北京市第六批老中醫藥專家學術經驗繼承工作指導老師
- 國家中醫藥重點學科「中醫乳腺病學」學科帶頭人
- 國家及北京市中西醫協同旗艦科室-普外科負責人
- 北京中醫藥大學中醫外科臨床系主任
- 國家標準化管理委員會-全國中醫標準化技術委員會委員

Triple-Negative Breast Cancer: Traditional Chinese Medicine-Driven Target and Drug Discovery

三陰性乳癌：中藥智慧驅動靶點發現與藥物研發

Prof. ZHANG Ge, Associate Dean of the School of Chinese Medicine at Hong Kong Baptist University & Director of Law Sau Fai Institute For Advancing Translational Medicine In

Bone & Joint Diseases

香港浸會大學中醫藥學院副院長、

羅守輝骨與關節疾病轉化醫學研究所所長 張戈教授 (Hong Kong)

Abstract 摘要

Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer with persistently unmet clinical needs. This study identified intracellular sclerostin as a novel therapeutic target for TNBC. Based on this discovery, we developed an aptamer drug modified with traditional Chinese medicine derivatives that effectively suppresses tumor progression and metastasis, thereby offering a novel therapeutic strategy for TNBC.

三陰性乳腺癌(TNBC)是侵襲性極強的乳腺癌亞型，其臨床需求仍未被滿足。本研究發現胞內硬骨抑素蛋白可作為TNBC新靶點。基於此，我們研發了中藥衍生物修飾的適配子藥物能夠有效抑制腫瘤進展與轉移，提供新型TNBC治療策略。

Speaker's Biography 講者簡介

Associate Dean of the School of Chinese Medicine at Hong Kong Baptist University and Director of Law Sau Fai Institute For Advancing Translational Medicine In Bone & Joint Diseases. Prof. Zhang's research focuses on the molecular mechanisms of tumor and musculoskeletal disorders as well as aptamer-based therapeutics, for which he has received multiple FDA Orphan Drug Designations. His representative works have been published in journals such as Nature Medicine, Nature Communications, and Nature Aging.

香港浸會大學中醫藥學院副院長、羅守輝骨與關節疾病轉化醫學研究所所長。張教授的研究聚焦於腫瘤科與骨科疾病的分子機制和適配子藥物(獲得多項FDA孤兒藥認證)。代表性成果發表在Nature Medicine、Nature Communication、Nature Aging等期刊。

Post-Market Evaluation Of Anti-Obese Effect Of A Panax Notoginseng Health Product

一款三七減肥保健產品的上市後再評價

Prof. WANG Ning, Associate Professor and Assistant Director (Research),
School of Chinese Medicine, The University of Hong Kong
香港大學中醫藥學院副教授、助理院長(研究) 王寧教授 (Hong Kong)

Abstract 摘要

Obesity involves adipose tissue expansion driven by genetics, diet, and lifestyle. Our previous work showed Panax notoginseng (PN) counteracts obesity via gut microbiota. In a 12-week clinical study, PN reduced BMI, waist-to-hip ratio, and visceral fat in obese patients. Mechanistically, PN suppressed gut microbiota-derived ceramide, elevating pulmonary SCGB3A2, which bound adipose macrophage MACRO receptors to induce lipolysis. This supports the gut–lung harmony concept in Traditional Chinese Medicine.

肥胖以脂肪組織增生為特徵。三七通過調節腸道菌群，在12週臨床試驗中有效降低患者BMI值、腰臀比及內臟脂肪。作用機制方面，三七能抑制菌源性神經醯胺生成，並上調肺部SCGB3A2蛋白表達，該蛋白通過結合巨噬細胞MACRO受體誘導脂肪分解。本研究為中醫肺腸軸理論提供了實證支持。

Speaker's Biography 講者簡介

Professor Wang Ning is currently the Associate Professor and Assistant Director (Research) of the School of Chinese Medicine of the University of Hong Kong (HKUSCM) and a National Youth Qihuang Scholar. He majorly is interested in translational researches related to novel targets, mechanisms of action and bioactive components from Chinese Medicines for the treatment of human cancers and metabolic diseases. He has published 160 papers in renowned international peer-reviewed journals, and edited 20 books and book chapters. He has been continuously listed as Top 1% Global Scholars by Clarivate and Top 2% Scientists by Stanford University since 2022.

王寧教授現任香港大學中醫藥學院副教授、助理院長(研究)及國家青年岐黃學者。他主要致力於中藥治療人類癌症及代謝性疾病的新型作用靶點、作用機制及生物活性成分相關的轉譯研究，已在國際知名同行評審期刊發表160篇論文，並主編20本專著及書籍章節。自2022年起持續獲科睿唯安評選為「全球前1%頂尖科學家」，並入選史丹福大學「全球前2%頂尖科學家」名單。

Exploring the Efficacy and Safety of Novel Chinese Medicine Formula Against Gout : Preclinical and Clinical Studies

新型臨床經驗方治療痛風的臨床前及臨床研究

Prof. XIAN Yanfang Lisa, Assistant Professor, School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong
香港中文大學醫學院中醫學院助理教授 冼彥芳教授 (Hong Kong)

Abstract 摘要

Gout Formula (GF), an empirical Chinese medicine formula, contains 15 Chinese herbal medicines. Our results revealed that GF significantly reduced urate burden, and ameliorated renal injury by regulating the urate metabolism and AMPK/TLR4/NLRP3 axis induced by potassium oxonate and hypoxanthine in mice. Acute and sub-chronic toxicity studies indicated that GF did not exert any overt toxicity. More importantly, our pilot clinical study demonstrated that GF could reduce the serum uric acid level and improve the health-related quality of life (HRQOL) of the gout patient assessing by Short Form-36 (SF-36) at weeks 8, and no overt adverse effect was found.

痛風配方 (GF) 是一種臨床經驗中藥複方，含有15種中藥。我們的研究結果表明，GF通過調節由氧代酸鉀和次黃嘌呤誘導的高尿酸小鼠模型的尿酸代謝和AMPK/TLR4/NLRP3軸，顯著降低尿酸負荷，並改善腎損傷。急性和亞慢性毒性研究表明，GF沒有產生任何明顯的毒性。更重要的是，我們初步的臨床研究表明，GF可以降低血清尿酸水準，改善痛風患者在第8周通過簡明36型 (SF-36) 評估的健康相關生活品質 (HRQOL)，並且沒有發現明顯的不良反應。

Speaker's Biography 講者簡介

Prof. XIAN Yan-Fang, Young Qihuang Scholar, is the Assistant Professor at School of Chinese Medicine, The Chinese University of Hong Kong. Prof. Xian is the Programme Director of Master Science in Chinese Medicine and Deputy Programme Director of Master Science in Chinese Medicine Pharmacology and Drug Development. Prof. Xian obtained her PhD degree in 2013 from The Chinese University of Hong Kong. Her research interests are the pharmacology of Chinese medicine in Alzheimer's disease, various solid cancer and Metabolic disease. Over the past 8 years, she had successfully obtained more than ten external competitive grants as PI. So far, Prof. Xian has published more than 120 original research articles based on her experimental findings in various SCI-listed academic journals such as Molecular cancer, Drug Resistance Updates, Acta Pharmaceutica Sinica B, Journal of Experimental & Clinical Cancer Research, Journal of Advanced Research, and Journal of Neuroinflammation with the H-index of 47 of Google Scholar. In addition, Prof. Xian listed as World's Top 2% Scientists by Stanford University in 2024 and 2025.

冼彥芳博士，青年岐黃學者，現任香港中文大學中醫學院助理教授，中醫學理學碩士課程主任，中藥藥理和藥物開發理學碩士課程副主任，博士生導師。冼博士於2013年獲得香港中文大學中醫哲學博士學位，長期專注於中藥治療腫瘤及阿爾茨海默病的臨床前研究。至今，冼博士已在Molecular cancer, Drug Resistance Updates, Acta Pharmaceutica Sinica B, Journal of Experimental & Clinical Cancer Research, Journal of Advanced Research, Journal of Neuroinflammation等國際知名雜誌上發表SCI論文120餘篇。其論文總引用次數超過5,600次，H指數：47 (Google Scholar)。以專案主持人的身份主持國家自然科學基金項目 (NSFC)、廣東省自然科學基金面上項目 (NSFGD)、香港醫務衛生局及創新科技局項目等10多項科研項目，擔任Phytomedicine, Acta Materia Medica (AMM)雜誌的編委，Chinese Medicine, Chinese Medicine and Culture等多本雜誌的青年編委，及入選2024、2025全球前2%頂尖科學家榜單 (World's Top 2% Scientists)。

Development of an Integrated Traditional Chinese and Western Medicine System for Chest Pain Management and Resuscitation: From Bench to Clinical Application of Suxiao Jiuxin Pill

中西醫結合胸痛與復蘇體系建設 - 速效救心丸的研發到應用

Prof. Chunjie LI, Chief Physician, Tianjin Chest Hospital
天津市胸科醫院主任醫師 李春潔教授 (Chinese Mainland)

Abstract

This presentation introduces the Tianjin experience in building an integrated Traditional Chinese and Western Medicine chest pain and resuscitation system. It highlights the establishment of a regional, multi-level network linking chest pain centers, treatment units, emergency medical services, and community healthcare to improve timely diagnosis and treatment of acute cardiovascular diseases. The presentation also discusses the integration of Traditional Chinese Medicine into emergency care, including pre-hospital management and multidisciplinary collaboration. In addition, the ongoing SPEED clinical studies will be introduced to demonstrate the clinical value and future potential of evidence-based integrated medicine in chest pain management.

本次報告系統介紹天津市在構建中西醫結合胸痛與復蘇體系方面的創新實踐與建設經驗，重點闡述以胸痛中心、胸痛救治單元、院前急救體系及基層醫療機構為依託，構建區域協同、多層級聯動的胸痛防治網路，實現急性心血管疾病救治鏈條的優化與救治效率的持續提升。報告將進一步分享中醫藥深度融入胸痛急救體系的實踐路徑，包括院前急救、中西醫多學科協同診療及全過程綜合干預模式，並介紹SPEED系列臨床研究的最新進展，展示循證醫學支持下中西醫結合在胸痛救治中的臨床價值及其未來發展前景，為構建更加高效、規範、可推廣的胸痛救治體系提供“天津經驗”。

Speaker's Biography

Chunjie Li, PhD, is a Chief Physician and doctoral supervisor at Nankai University, Tianjin University, and Tianjin University of Traditional Chinese Medicine. His expertise includes cardiovascular emergency and critical care, post-treatment rehabilitation, and integrated Traditional Chinese and Western medicine for cardiovascular diseases. He currently serves as President of the Tianjin Society for Chest Pain and Resuscitation, Deputy Director of the Institute of Emergency Medicine at Tianjin University, and Director of the Emergency Department at Tianjin Chest Hospital.

李春潔，主任醫師，博士，南開大學、天津大學、天津中醫藥大學博士生導師，擅長心血管危急重症的救治和預後康復、心血管疾病中西醫聯合診治。現任天津市胸痛與復蘇學會會長、天津大學醫學部應急醫學研究院副院長、天津市胸科醫院急診科行政主任。

Session 4

第四節

Successful Cases Sharing

成功個案分享

Sharing Valuable Experience on: The Application and Effectiveness of Good Manufacturing Practice (GMP) for Proprietary Chinese Medicines and the Hong Kong Chinese Materia Medica Standards (HKCMMS) in the Industry, as well as International Marketing of Chinese Medicine

分享中成藥生產質量管理規範(GMP)、《港標》在業界應用方案及成效、及中藥國際化市場營銷的寶貴經驗

Dr. Celine CHENG, Chief Compliance &
Technology Officer of Jacobson Pharma Corporation Limited
雅各臣科研製藥有限公司首席合規及技術總監 鄭香郡博士 (Hong Kong)

Abstract 摘要

Good Manufacturing Practice (GMP) has been the global gold standard for drug product quality for more than six decades. GMP was introduced to the manufacturing and quality control of Proprietary Chinese Medicines (pCm) in 2003. A prerequisite for obtaining global regulatory approval and market access for pCm in countries such as Mainland China, Singapore, Australia, Canada, and Europe is GMP compliance, which ensures the production of safe and consistent quality products by establishing standards for pCm manufacturing hardware and software, including raw materials, premises, equipment, sanitation, personnel training, and quality management. The implementation of GMP undoubtedly reduces cross-contamination risks and batch to-batch variability, and helps lower and control the levels of heavy metals, pesticides, and microbial limits. The HKCMMS, launched by the Department of Health, was developed to assist manufacturers as a guide for the quality control of raw materials and to allow for the effective differentiation of adulterants and substitutes. GMP certification coupled with HKCMMS-aligned testing will enable Hong Kong pCm manufacturers to successfully enter global markets. The synergistic application of GMP and HKCMMS will substantially further elevate the safety, quality, and traceability of products while expediting the standardization, modernization, and internationalization of the proprietary Chinese medicines manufacturing industry. It will also boost public confidence in using pCm and facilitate global trade.

良好生產規範(GMP)作為藥品品質的全球黃金標準已逾六十載。自2003年起，GMP制度被引入中成藥(pCm)的生產及質量控制領域。在中國內地、新加坡、澳洲、加拿大及歐洲等國家地區，中成藥要獲得監管批准與市場准入，符合GMP標準是必要條件。該標準通過對中成藥生產硬件設施(包括原材料、廠房、設備、衛生條件)與軟件系統(人員培訓、質量管理)建立規範，確保生產出品質安全穩定的產品。GMP的推行無疑能降低交叉污染風險與批次間差異，並有助管控重金屬、農藥殘留及微生物限量水平。香港衛生署推出的《香港中藥材標準》(HKCMMS)，旨在為生產商提供原料質量控制指引，有效鑑別混雜品與替代品。GMP認證配合符合HKCMMS標準的檢測，將助力香港中成藥生產商成功進軍國際市場。GMP與HKCMMS的協同應用，不僅能顯著提升產品安全性、品質與可追溯性，更將加速中成藥產業的標準化、現代化與國際化進程，同時增強公眾使用中成藥的信心並促進全球貿易發展。

Speaker's Biography 講者簡介

Dr. Celine Cheng is a registered pharmacist in both Hong Kong and the United Kingdom and a registered Authorized Person with the Pharmacy & Poison Board of Hong Kong. She earned her Ph.D. in pharmacology from the University of Bradford, UK. She also obtained a Master of Business Administration degree from the City University of Hong Kong. She has been the President of the Hong Kong Pharmaceutical Manufacturers Association since 2008. She has worked tirelessly in raising the GMP standards in the Hong Kong pharmaceutical manufacturing industry and achieving PIC/S GMP standard. She has over 30 years of hands-on experiences in sterile and non-sterile manufacturing, quality assurance and GMP specializing in quality management system reengineering for pharmaceutical, biological products and proprietary Chinese medicines. She currently serves as Chief Compliance & Technology Officer for the Jacobson Pharma Group and Executive Director for JBM (Healthcare) Limited.

鄭靜琳博士擁有香港及英國雙重註冊藥劑師資格，同時獲香港藥劑業及毒藥管理局認可為法定負責人。她取得英國布拉德福德大學藥理學博士學位，並持有香港城市大學工商管理碩士學位。自2008年起出任香港製藥廠商會會長，長期致力提升香港藥品製造業的GMP標準，成功協助業界達致國際醫藥品稽查協約組織(PIC/S)GMP規範。鄭博士在無菌及非無菌藥品生產、質量保證與GMP管理領域累積逾30年實務經驗，專精於藥品、生物製品及中成藥質量管理體系重組工程。現任雅各臣科研製藥集團首席合規及科技總監，並擔任健倍苗苗(保健)有限公司執行董事。

Modernization and Internationalization of Traditional Chinese Medicine and Acupuncture Education in North America

北美中醫藥針灸教育的現代化與國際化發展

Prof. David Dong LIU, Professor, School of Health,
Wellness and Sciences, Georgian College
加拿大喬治亞應用文理學院健康、福祉與科學系教授 劉東教授 (Canada)

Abstract 摘要

The modernization of Traditional Chinese Medicine and acupuncture education in North America has been driven by regulatory development, competency-based curricula, integration of biomedical sciences, evidence-informed practice, and quality assurance mechanisms. Under U.S. acupuncture legislation, the professional title is uniformly "acupuncturist," with education offered at master's and doctoral levels, following an academic model where degrees are independent of professional titles. Under Canada's comprehensive TCM and acupuncture legislation, titles are divided into three categories: acupuncturist, TCM practitioner, and Dr.TCM. Training is based on professional competencies with corresponding programs, following a professional model where titles align with program offerings. The U.S. model emphasizes academic research, has a single title, and features simple management; the Canadian model has clear hierarchical distinctions but more complex certification. Comparing the two models and drawing mutual lessons is of great significance for promoting standardization of basic training and systematization of continuing education, strengthening the integration of evidence-based medicine with TCM, advancing the international development, professional mobility, and global recognition.

北美中醫藥與針灸教育的現代化發展，包括法規制度的建設、能力導向的課程設置、以及中西醫知識的整合。美加兩國中醫立法差異決定了北美中醫藥與針灸教育模式的不同。美國在針灸立法下，頭銜統一為針灸師，教育設碩士、博士課程，屬學術型模式，學位與頭銜無關。加拿大在中醫針灸整體立法下，頭銜分為針灸師、中醫師、高級中醫師三類，培訓基於專業技能標準設立對應課程，屬專業型模式，頭銜與課程相對應。美國模式側重學術研究，頭銜單一，管理簡便；加拿大模式分級清晰，但認證較為複雜。比較兩國模式並相互借鑒，對於推動基礎培訓標準化與繼續教育體系化、加強循證醫學與中醫融合、促進中醫國際化發展，以及促進國際學術合作，以提升教育品質、專業流動性及全球認可度具有重要意義。

Speaker's Biography 講者簡介

Prof. David Dong Liu is a Canadian educator, clinician, and researcher specializing in Traditional Chinese Medicine, acupuncture, neuro rehabilitation and sport injury prevention and recovery. He earned a doctor degree in Acupuncture from Heilongjiang University of Chinese Medicine, a master's degree in Kinesiology and Health from the University of Texas, and pursued advanced studies in psychomotor behavior at York University. His clinical experience encompasses pain management, sports injury treatment, stroke rehabilitation, and spinal cord injury rehabilitation. He has provided support at international figure skating championships and worked with Canadian Olympic track and field athletes. Actively engaged in evidence-informed acupuncture practice and education, Prof. Liu is also a dedicated practitioner and advocate of Tai Chi and Dao Yin. In recognition of his professional and educational contributions, he has received the International Contribution Award in Traditional Chinese Medicine, the Ontario Mental Health Medal, and the Georgian College Excellence in Education Award. Award.

劉東博士，加拿大神經運動康復與中醫針灸教授。黑龍江中醫藥大學中醫針灸學博士，美國德州大學運動健康碩士，加拿大約克大學心理運動行為課程進修。對疼痛、運動創傷、睡眠、眼科保健、中風後遺症及脊髓損傷復健、膀胱排尿功能治療有豐富臨床經驗；作為運動治療師，多次隨隊參加國際花式滑冰錦標賽，服務加拿大國家田徑隊及牙買加短跑運動員。劉東博士積極從事中醫針灸臨床實證研究，探索運動、疼痛與睡眠及身心健康。劉東博士熱愛太極拳，曾參加2017加拿大多倫多國際太極拳錦標賽。2018年與2024年兩度獲得了加拿大多倫多國際中醫藥針灸發展與貢獻獎。2025年分別獲得安省衛生廳心理健康獎章及喬治亞學院優秀教育工作者嘉獎。

Sharing Experiences and Outcomes from Chinese Medicine Practitioner Training in Australia

分享澳大利亞中醫人才培訓經驗及成果

Prof. ZHU Xiaoshu, Co-Director, Australia-China Chinese Medicine Centre,
Western Sydney University, Australia
澳大利亞西悉尼大學中澳中醫中心聯席主任 朱小紓教授 (Australia)

Abstract 摘要

This presentation shares the experiences and outcomes of Chinese medicine practitioner training in Australia, drawing on the experience of Western Sydney University — the only Australian public university offering a comprehensive suite of accredited Chinese medicine degree programs.

The paper highlights developments in evidence-based education, interprofessional clinical training, international immersion, research integration, and multicultural healthcare practice in the West. It further reflects on how Australia is not simply replicating educational models from China, but developing a distinctive international model of Traditional Chinese Medicine education that preserves traditional foundations while responding to contemporary healthcare, regulatory, and global practice environments.

本報告以西雪梨大學中醫人才培養體系為例，分享澳大利亞中醫教育的發展經驗與實踐成果。作為澳大利亞唯一開設完整中醫高等學歷課程體系的公立大學，西雪梨大學在實證教育、跨專業臨床實踐、國際化臨床培養、科研融合以及多元文化醫療服務等方面，逐步形成具國際特色的中醫人才培養模式。

報告同時探討澳大利亞中醫教育如何在保持中醫傳統理論與核心特色的基礎上，積極回應現代醫療體系、行業監管及全球化發展的需求，探索出一條有別於中國本土模式的國際化中醫教育路徑。

Speaker's Biography 講者簡介

Professor Xiaoshu Zhu is Co-Director of the Australia – China Chinese Medicine Centre, a flagship collaboration established under the China–Australia Free Trade Agreement. She is Honorary Professor of Beijing University of Chinese Medicine and Nanjing University of Chinese Medicine.

She has secured over A\$3.75 million in competitive and philanthropic funding and contributed to establishing a \$2 million cancer survivorship research facility serving the Greater Western Sydney region.

As an advisor to the World Health Organization (WHO), a long-standing International Organization for Standardization (ISO) TC249 member, and an inaugural member of the Chinese Medicine Board of Australia (CMBA), she has shaped global health standards and national regulations. Her visionary leadership has transformed integrative healthcare models, addressing unmet needs through culturally responsive, evidence-based approaches, positioning Western at the forefront of inclusive STEM innovation.

朱小紓教授現任中澳中醫中心創始聯席主任。該中心由西雪梨大學與北京中醫藥大學合作建立，係2014年《中澳自由貿易協定》簽署後兩國中醫藥領域重要合作成果之一，並獲中國國家中醫藥管理局授權設立為海外中醫藥中心。

朱教授是國際知名中醫藥學者，在中醫高等教育、課程評估、教學創新及國際學術合作方面具備豐富經驗。她長期擔任西雪梨大學中醫學術課程負責人，領導澳大利亞唯一公立大學完整的中醫學位體系。同時，她受聘為北京中醫藥大學與南京中醫藥大學客座教授及博士生導師。

朱教授在中西醫結合腫瘤研究領域具有國際影響力，致力以循證研究推動中醫藥在腫瘤整合醫學中的應用。她同時積極參與國際標準與政策制定，身兼世界衛生組織(WHO)顧問、國際標準化組織ISO TC249委員及澳大利亞中醫管理局創始成員。其研究獲ARC-Linkage、NIH、NSFC、NBCF及DFAT等機構資助，並因學術貢獻獲頒多項國際與澳大利亞獎項。

The Impact of Modern Life Science Development on the Cultivation of Top-Notch Innovative Talents in Chinese Materia Medica

現代生命科學發展對中藥學拔尖創新人才培養的影響

Prof. XU Hongxi, Chairman, Belt and Road Alliance for Traditional Medicine; Honorary Dean & Distinguished Professor, Shanghai University of Traditional Chinese Medicine
「一帶一路」中醫藥發展聯盟主席、上海中醫藥大學首席教授、
中藥學院名譽院長 徐宏喜教授 (Chinese Mainland)

Abstract 摘要

The rapid advancement of life sciences is fundamentally transforming the disciplinary landscape of Chinese Materia Medica and redefining the competencies required of future professionals. Emerging technologies, including genomics, single-cell sequencing, artificial intelligence, bioinformatics, and synthetic biology, have provided powerful tools for elucidating the pharmacological basis, mechanisms of action, and clinical value of Chinese medicines, while accelerating interdisciplinary integration between traditional medicine and modern biomedical sciences. This presentation examines the impact of life science development on the cultivation of top-notch innovative talents in Chinese Materia Medica. Particular emphasis will be placed on interdisciplinary knowledge integration, scientific thinking, innovation capacity, and global competence. Strategies for developing a talent cultivation framework that integrates traditional Chinese medicine knowledge with contemporary life science approaches will also be discussed, with the aim of fostering future leaders capable of advancing the modernization and internationalization of Chinese Materia Medica.

現代生命科學的快速發展正在深刻改變中藥學研究範式。從基因編輯、單細胞測序、人工智能到合成生物學等前沿技術的突破，為中藥藥效物質基礎解析、作用機制研究、新藥研發及國際化發展提供了新的機遇。本報告結合生命科學領域最新進展和中藥創新研究案例，探討現代生命科學對中藥學學科發展的推動作用，以及對拔尖創新人才培養提出的新要求。重點圍繞學科交叉融合、創新思維培養、國際視野拓展和人工智能賦能教育等方面，探討新時代中藥學高層次人才培養的新路徑與新模式。

Speaker's Biography 講者簡介

Professor Xu Hongxi is the Honorary Dean of the School of Pharmacy at Shanghai University of Traditional Chinese Medicine. He serves as Chairman of the Belt and Road Alliance for Traditional Medicine and Secretary-General of the National Advisory Committee on Materia Medica.

Internationally, he is a Visiting Professor at Nanyang Technological University (Singapore), Honorary Professor at The University of Hong Kong, and Editor-in-Chief of Acta Materia Medica (AMM). His research focuses on identifying active components in traditional medicine and elucidating their pharmacological mechanisms. He has authored over 450 SCI papers, with an h-index of 82 and more than 24,000 citations.

Professor Xu is consistently ranked among the top 2% of scientists worldwide by Stanford University and has been named a “Highly Cited Chinese Researcher” for 12 consecutive years. He has visited over 100 countries to advance the globalization of traditional medicine.

徐宏喜，國家中組部特聘專家、國務院學位辦中藥學科評議組秘書長、一帶一路中醫藥發展聯盟主席，新加坡南洋理工大學特聘教授、香港大學榮譽教授及AMM主編。發表SCI論文450餘篇，H指數82。連續12年入選「中國高被引學者」，上榜史丹佛「終身科學影響力榜單」。

Exploring the Demand Characteristics for Chinese Medicine Products in Potential Markets such as ASEAN and Belt and Road Initiative Countries

探討東盟、一帶一路沿線等潛力市場對中藥產品的需求特點

Prof. Linda ZHONG, Director, Biomedical Sciences and Chinese Medicine,
School of Biological Sciences,
Nanyang Technological University, Singapore
新加坡南洋理工大學生物科學學院生物醫學及中醫學主任 鍾麗丹教授 (Singapore)

Abstract 摘要

With the internationalization of Traditional Chinese Medicine (TCM), ASEAN countries and regions along the Belt and Road Initiative have become promising markets for Chinese herbal medicine products. This presentation will explore the role of Chinese herbal medicine products in chronic disease management and health maintenance, based on factors such as demographics, disease burden, usage habits of herbal products, and regulatory policies. It will further analyze the opportunities and challenges in the international development of Chinese herbal medicine products.

隨著中醫藥國際化，東盟國家及「一帶一路」沿線地區成為中藥產品拓展的潛力市場。本講座將基於人口結構、疾病負擔、中藥產品使用習慣及監管政策等因素，探討中藥產品在慢性病管理及養生保健領域的市場定位，分析其中的機遇與挑戰。

Speaker's Biography 講者簡介

Prof. Linda Zhong is currently Director of Chinese Medicine and Biomedical Sciences at Nanyang Technological University, Singapore. Equipped with Bachelor in Chinese Medicine, Master of Integrative and Chinese Medicine in Shanghai University of TCM, and Doctor of Philosophy (PhD) in Chinese Medicine clinical research at the University of Hong Kong (HKU), Dr. Zhong has worked in Chinese Medicine education, research, and service for more than 20 years.

She has designed and conducted more than 50 clinical studies with broad scope of diseases and interventions and successfully applied different levels of grants from government. Totally, she has obtained 19 clinical research projects as Principal Investigator and edited more than 10 books of Chinese Medicine and Integrated Medicine.

Her research focuses mainly on integrative medicine and globalization of Chinese Medicine. She is also a Visiting Professor of Integrative Medicine Centre, the University of Toronto, and Visiting Fellow of Australian Research Centre for Complementary and Integrative Medicine, the University of Technology Sydney. Currently she serves as the committee members of Singapore MOH TCMPB research and development and Healthier SG. In 2020, she was awarded Qi Huang Young Scholar by the State Administration of Traditional Chinese Medicine in recognition of her excellence in clinical practice and studies of Chinese medicine.

鍾麗丹教授現任新加坡南洋理工大學中醫與生物醫學系主任，擁有上海中醫藥大學中醫臨床學士、中西醫結合碩士及香港大學中醫臨床研究博士。她在中醫的教學、科研和服務領域已有20多年的工作經驗。

她曾設計並開展了50多項涉及不同疾病及干預措施的臨床研究，並成功申請了不同層次的政府資助研究項目，作為研究負責人獲得了19個臨床研究項目，並編輯了超過十本的中醫及結合醫學的中英文專業書籍。

她的研究主要集中在結合醫學及中醫藥國際化研究。她還是多倫多大學結合醫學中心的訪問教授及悉尼科技大學澳大利亞補充與結合醫學的訪問學者。目前她還擔任新加坡衛生部中醫藥管理委員會中醫藥科研與發展以及健康SG的委員會成員。2020年被國家中醫藥管理局授予首屆青年岐黃學者稱號，以表彰其在中醫藥臨床實踐及研究領域方面的卓越成就。

Genuine Medicine Market Centralized Trading — SC Chinese Medicine Trading Platform 正藥市場·集中交易—守創中藥貿易平台

Mr. SU Shutao, General Manager, Guangzhou SC Chinese Medicine Co., Ltd.
廣州守創中藥有限公司（守創中藥貿易平台）總經理 蘇樹濤先生 (Chinese Mainland)

Abstract 摘要

The Shouchuang Chinese Medicine Trading Platform offers a full industrial chain of online trade services for the industry, integrating transaction settlement, information release, logistics tracking, product display, and price disclosure. It covers all links of the industrial chain, including the cultivation, processing, circulation, decoction piece production, pharmaceuticals, and medical care of traditional Chinese medicinal materials, providing the industry with a solution for genuine medicine trade.

守創中藥貿易平台為業界提供全產業鏈的線上貿易，集交易結算、資訊發佈、物流追蹤、貨品展示、價格公示於一體，涵蓋中藥材種植、加工、流通、飲片生產、製藥、醫療等全產業鏈環節，為行業提供正藥貿易解決方案。

Speaker's Biography 講者簡介

Su Shutao is General Manager of the Shouchuang Chinese Medicine Trading Platform under the TCM All-sector Hong Kong Centre. He also serves as a Standing Committee Member of the China Association of Traditional Chinese Medicine (CATCM).

Previously, he held senior management positions at the Dalian Commodity Exchange (DCE) and at an A-share listed traditional Chinese medicine (TCM) enterprise. He led the development of the Chinese herbal medicine price index and pioneered innovative trading systems including warehouse receipt trading and order-based trading for Chinese herbal medicines.

蘇樹濤現任中醫藥全產業鏈香港中心旗下守創中藥貿易平台總經理，同時擔任中國中藥協會(CATCM)常務理事。曾任職於大連商品交易所，並在A股上市中醫藥企業擔任高階主管。主編《中藥材價格指數》，提出中藥材倉單、訂單交易體系。

Qualification, Registration, Duties, and Responsibilities of Pharmacist Specialised in Traditional Chinese Medicine (TCM) 澳門中藥師專業資格註冊制度及其核心職能

Mr. LAO Chi Chou, Vice Director,
Association of Pharmacists of Chinese Medicine of Macao
澳門中藥師學會副會長 劉智祖先生 (Macao)

Abstract 摘要

Macau's previous regulations, including Decree-Laws No. 84/90/M and 58/90/M, only governed medical facilities, but lacked standardized rules for qualifications and practice of medical personnel, leading to fragmented supervision. Law No. 18/2020, approved in 2020 and effective in October 2021, standardized qualification, registration and practice of medical staff, and established the Medical Council. The law emphasized on the responsibilities of TCM pharmacists including prescription verification, dispensing, consultation, quality testing and pharmacy management. Decree-Law No. 53/94/M of 1994 regulated traditional Chinese medicine (TCM) premises, while Law No. 11/2021 expanded supervision to pharmaceutical activities and proprietary Chinese medicine registration.

澳門原有醫療與中藥監管制度分散，法令84/90/M和58/90/M僅規管場所，缺乏人員資格與執業統一規範。為完善監管、保障醫療及藥品安全，澳門逐步推動立法與機構改革。

2020年通過第18/2020 號法律，統一醫療人員資格、註冊及執業監管，設立醫療專業委員會，於 2021年10月生效。中藥領域方面，同時，法律明確中藥師執業範圍，包括處方審核、炮製調劑、用藥諮詢、質量檢驗及藥事管理等職務。

1994年第53/94/M 號規範中藥場所准照；2021年第11/2021號法律擴大至藥事活動與中成藥註冊，制度更全面。

Speaker's Biography 講者簡介

Lao Chi Chou received his Master's degree Master of Pharmacology in Traditional Chinese Medicine in 2022. He obtained the professional qualification of Macau Chinese Medicine Practitioner in 2023.

He is currently working at the Macao Centre for Testing of Chinese Medicine, University of Macau, mainly responsible for the testing of proprietary Chinese medicines.

His research focuses on Chinese medicine analysis, molecular pharmacognosy and quality control of Chinese medicines.

He has been developing new methods and molecular markers for quality control of Chinese medicinal materials at the genetic level, and using bioinformatics techniques to identify authentic Chinese medicines rapidly and accurately. He has published 13 academic papers and authorized 1 international and domestic patent.

劉智祖，2022 年取得澳門科技大學中醫藥學院中藥學碩士學位，2023 年獲頒澳門中藥師專業資格認證。現任職於澳門大學澳門中藥檢測中心，專責中藥及中成藥檢測相關工作。

主要研究領域涵蓋中藥分析、分子生藥學與中藥質量控制，開發中藥質量相關分子標記與鑒定技術，實現藥材真偽之快速、精準判別；同時以化學成分分析為核心，確認藥材真偽及有效成分含量是否符合《中國藥典》標準。

迄今發表學術論文 13 篇，獲國際及國內專利授權 1 項。

Honor the Virtue of Our Roots. Heal the World of Tomorrow 傳承同修仁德底蘊 開闢濟世養生全球健康新征程

Mr. YAN Han, Chairman, Beijing Tong Ren Tang Chinese Medicine Company Limited
北京同仁堂國藥有限公司董事長 嚴晗先生 (Chinese Mainland)

Abstract 摘要

Tong Ren Tang boasts a 350-year heritage, founded on the philosophy of "promote people's health with noble morality and kindness" With over three decades of overseas operations, it has established more than 160 retail outlets across 26 countries and regions worldwide, building an integrated international framework centered on production bases, retail networks, medical services, and cultural outreach.

Globally, Tong Ren Tang seeks to draw on its brand legacy, align with the global health cooperation agenda, and leverage the strengths of traditional medicine—to deliver health solutions rooted in China to people everywhere, while sharing Eastern wellness philosophies and Chinese wisdom with the world.

同仁堂以350餘年「同修仁德 濟世養生」的深厚底蘊為根基，深耕海外三十餘載，已覆蓋全球26個國家和地區，佈局160餘個境外零售終端，建構「生產基地為核能、零售終端為網、醫療服務基、文化傳播為脈」的四位國際化體系。

Speaker's Biography 講者簡介

Yan Han, is an Executive Director and the chairman of the board of directors of the Beijing Tong Ren Tang Chinese Medicine CO.,LTD. Mr. Yan joined Beijing Tong Ren Tang Group in June 2024, and is currently the assistant of general manager, the manager of the Publicity Department and the Cultural Heritage Center of Tong Ren Tang Holdings. Mr. Yan had held senior and mid-level leadership positions for years in government departments and international organisations such as Beijing World Tourism City Development Center* (北京市世界旅遊城市發展中心), the World Tourism Cities Federation, and Beijing Organizing Committee for the 2022 Olympic and Paralympic Winter Games. Mr. Yan has been engaged in international culture publicity and brand development for a long time, has led the establishment of the first Chinese-initiated international tourism organization, the World Tourism Cities Federation, has organized a number of major international events in over 20 countries across Asia, Europe, and North America, and has excellent international cooperation resources. Mr. Yan obtained a master's degree in international relations from the Peking University in June 2008, and obtained a Ph.D. degree in international relations from the China Institutes of Contemporary International Relations in June 2021.

嚴晗，北京同仁堂國藥有限公司執行董事及董事會主席。嚴先生於2024年6月加入北京同仁堂集團，現任同仁堂集團公司總經理助理、宣傳部及文化傳承中心部長職務。嚴先生曾在北京市世界旅遊城市發展中心、世界旅遊城市聯合會、北京2022年冬奧會和冬殘奧會組織委員會等政府部門和國際組織擔任多年高層和中層領導職務。嚴先生長期從事對外文化宣傳和品牌推廣工作，主持成立首個中國發起國際旅遊組織——世界旅遊城市聯合會，在亞洲、歐洲、北美洲等20多個國家舉辦多項重大國際會議活動，具有良好的國際合作資源。嚴先生於2008年6月於北京大學取得國際關係碩士學位，並於2021年6月獲中國現代國際關係研究院授予國際關係博士學位。

Rooted in Hong Kong, Reaching Across Borders — A Two-Way Future for TCM

立足香江融通兩地，打造中醫藥雙向發展新格局

Mr. LI Xiusheng, General Manager,
Hong Kong Fangsheng Tang Pharmaceutical Co., Limited
香港方盛堂大藥廠有限公司總經理 黎秀盛先生 (Hong Kong)

Abstract 摘要

香港方盛堂大藥廠有限公司介紹了企業赴港佈局GMP生產基地的經驗，內容涵蓋生產基地建設、產品矩陣佈局、市場渠道搭建、創新商業模式拓展、合規體系管控、產學研合作六大板塊。重點推出涵蓋委託加工、委託檢驗、委託註冊的一站式服務，並闡述企業融通兩地、推動中藥國際化的發展路徑與規劃。

Speaker's Biography 講者簡介

Li Xiusheng graduated from China Pharmaceutical University with a major in Traditional Chinese Medicine (TCM) Pharmaceutical Manufacturing. With over twenty years of deep-rooted experience in the TCM industry, he has long served as a senior executive in multiple TCM manufacturing enterprises in both Mainland China and Hong Kong. Consistently dedicated to the collaborative development of the TCM industries across the two regions, he possesses a profound understanding of policies, markets, and culture, enabling him to accurately identify the challenges and opportunities for mainland enterprises "going global." He is particularly adept at assisting mainland companies in establishing a presence in Hong Kong and aligning with international standards. With unique insights into promoting the internationalization of TCM, he has accumulated a wealth of successful cases in this field.

黎秀盛，畢業於中國藥科大學中藥製藥專業，擁有逾二十多年中醫藥行業深耕經驗。長期擔任內地及香港多家中藥製造企業的高管。始終專注於兩地中醫藥產業的協同發展，憑藉對政策、市場與文化的深刻理解，精準把握內地企業“走出去”的痛點與機遇。尤為擅長協助內地企業通過落地香港、接軌國際，在推動中醫藥國際化方面見解獨到，並積累了豐富的成功案例。

The 22nd International Postgraduates Symposium on Chinese Medicine (IPSCM)

第二十二屆國際研究生中醫藥研討會

Programme Book

會議手冊

Hong Kong Convention and Exhibition Center
香港會議展覽中心

August 15, 2026 (Onsite & Online Symposium)



Joint-organisers:

ISBN 978-9-88-753705-2



9 789887 537052 >



WELCOME MESSAGE

Dear participants,

On the occasion of the 22nd International Postgraduates Symposium on Chinese Medicine (IPSCM), on behalf of the Organizing Committee, I would like to extend our warmest welcome and most sincere greetings to all students and friends. Regardless of where you come from or which field you represent, our gathering here today, driven by a shared vision, is the perfect embodiment of the conference's core spirit: “Communication, Collaboration, and Innovation”.

We understand that in an era of rapid change, only through open dialogue and cross-disciplinary collaboration can we push the boundaries of our understanding and generate truly valuable solutions. This conference has provided a platform for graduate students from different research aspects and countries to exchange ideas, and has sparked new inspiration through the exchange of ideas.

We deeply honor to invite more than 100 outstanding young scientists and friends from Hong Kong, Macau, Mainland China, Australia, Bangladesh, Indonesia, Malaysia, Myanmar, Pakistan, Serbia, Singapore, South Korea, Sri Lanka, Thailand, Vietnam, and other countries to present their research findings—including oral and poster presentations. This handbook contains the abstracts submitted by the students to facilitate the academic exchange among students.

As the convener of the Organizing Committee and leader of this year’s symposium, I would like to express my sincere appreciation to all members for the time and effort you have devoted to this event. I would like to thank your contributions to this event to make it was able to take place smoothly.

We would like to extend our special gratitude to the MCMIA Foundation, the Hong Kong Trade Development Council, the Chinese Medicine Development Fund, and other supporting organizations and partners. Their collaboration has been instrumental in bringing the 22nd IPSCM to life. We also thank all participating institutions of higher education—your strong support was the foundation for the success of this conference.

I wish this conference complete success! May you all gain insights, connect with like-minded colleagues, and join hands to breathe new life into the development of Chinese Medicine. Thank you once again for joining us, and I hope you all have a fulfilling and wonderful time here!

Yours truly,

Prof. LIN Zhixiu

Convener, Academic Advisory Board of the 22nd IPSCM

Director and Professor, School of Chinese Medicine, The Chinese University of Hong Kong

ACKNOWLEDGEMENTS

The Organizing Committee of the 22nd International Postgraduates Symposium on Chinese Medicine would like to express its sincere gratitude to the following institutions and sponsors for their generous support, which made the successful hosting of this symposium possible (listed in alphabetical order, in no particular order):

The Chinese University of Hong Kong

School of Chinese Medicine

The University of Hong Kong

School of Chinese Medicine; Institution of Chinese Medicine

The Hong Kong Baptist University

School of Chinese Medicine

The Hong Kong University of Science and Technology

School of Chinese Medicine; Division of Life Science

The Hong Kong Polytechnic University

Department of Food Science and Nutrition

University of Macau

Institution of Chinese Medicine Science

Nanyang Technological University

School of Chinese Medicine

Shanghai University of Traditional Chinese Medicine

School of Pharmacy

Guangzhou University of Chinese Medicine

School of Chinese Medicine

Guangzhou Medical University

Department of Traditional Chinese Medicine

Shenzhen University

School of Pharmacy

Shandong University of Traditional Chinese Medicine

Innovation Research Center

Hubei University of Chinese Medicine

School of Pharmacy

JiangyinTian Jiang Pharmaceutical Co. Ltd

MCMIA Foundation Limited

Hong Kong Trade Development Council

Chinese Medicine Development Fund

PROGRAMME

Date August 15, 2026

Time:08:30-13:20

Venue: Room N101

Time	Event	
08:30-09:10	Registration	
09:15-09:30	The 22 nd IPSCM Opening Ceremony	
09:30-09:40	“Vincent & Lily Woo Fellowship in Memory of Dr Albert Wong endowed by Vincent & Lily Woo Foundation” Award Presentation Ceremony - Opening Speech by Mr. Harry Yeung Chairman of MCMIA Foundation - Award Presentation Ceremony	
09:40-10:00	Presentations by 2025 Fellowship Recipients (LIN Ting Syuan & ZHANG Xueting)	
10:00-10:14	CHEN Jiayi	Guttiferone K induces apoptosis of quiescent prostate cancer cells via mitophagy-mediated downregulation of MRPS34 <i>School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Chinese Mainland</i>
10:14-10:28	Chae-Yeon Kang	Multi-Target Therapeutic Effects of Coptidis Rhizoma in Obesity, Dyslipidemia, and Type 2 Diabetes: Translational evidence from, In Silico, In Vivo, and Meta-Analysis studies <i>Department of Clinical Korean Medicine, Kyung Hee University, Korea</i>
10:28-10:42	REN Zhengyu	<i>Hericium erinaceus</i> Mycelium Polysaccharide Alleviates Spontaneous Ulcerative Colitis in Monkeys by Enhancing IPA-Mediated Macrophage Efferocytosis via Lysosomal Regulation <i>Institute of Chinese Medical Sciences, University of Macau, Macau</i>
10:42-10:56	LIANG Fuchao	Exosome-Enabled Oridonin-Based Bridged PROTACs for Targeted Androgen Receptor Degradation in Androgenetic Alopecia <i>School of Chinese Medicine, Hong Kong Baptist University, Hong Kong</i>
10:56-11:10	Wan-Jung CHENG	Cytochrome P450 Interactions Between Cardioprotective Chinese Herbal Medicines and Antiretroviral Drugs: A Systematic Review of In Vivo Evidence <i>School of Health and Biomedical Sciences, Royal Melbourne Institute of Technology (RMIT) University, Australia</i>
11:10-11:25	Break & Poster Session (N106-N108)	
11:25-11:39	NG Yan Jie Chester	Herb-Drug Interactions in Integrative Care: From Active Surveillance to Hypersensitivity, Diagnosis, and Policy <i>School of Biological Sciences, Nanyang Technological University, Singapore</i>
11:39-11:53	Tran Thi Hong Ngai	Gastroprotective Effects of Da Khoi Cot, A Traditional Vietnamese Polyherbal Decoction, Against Indomethacin-Induced Gastric Ulcer in Wistar rats <i>Vietnam University of Traditional Medicine, Vietnam</i>
11:53-12:07	LI Xiaofang	Screening and Characterization of a Novel Skeletal Muscle-Targeting Aptamer for Precise Delivery of Triptolide in Traditional Chinese Medicine Therapy of Muscle Inflammation <i>School of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong</i>
12:07-12:21	LIU Feiyang	Pulsatilla Decoction Granules Ameliorate Ulcerative Colitis by Activating the CTCF/VDR/GPX4 Pathway via the Gut Microbiota-C15:0 Axi <i>School of Chinese Medicine, Guangzhou University of Chinese Medicine, Chinese Mainland</i>
12:21-12:35	Aleksandra Mladenovic	Food as Medicine: Traditional Fermented Foods as Dietary Interventions for Neuroinflammation and Healthy Ageing <i>Mladenovic Institute for Biological Research, University of Belgrade, Serbia</i>
12:35-12:45	Break	
12:45-13:00	Award Presentation Ceremony	

Guttiferone K induces apoptosis of quiescent prostate cancer cells via mitophagy-mediated downregulation of MRPS34

藤黄酮 K 调控线粒体自噬下调 MRPS34 诱导静止期前列腺癌细胞凋亡

Jiayi CHEN, Mengfan LIU, Xue JIANG, Zhichao XI, Hongxi XU

School of Pharmacy, Shanghai University of Traditional Chinese Medicine

Background Disease recurrence remains a major clinical challenge in prostate cancer and is frequently associated with metastatic progression and poor prognosis. A subpopulation of chemotherapy-tolerant quiescent cancer cells (QCCs) can survive cytotoxic treatment in a dormant state and subsequently re-enter the cell cycle, thereby driving tumor relapse. Eliminating QCCs before their reactivation may therefore represent an effective strategy for preventing prostate cancer recurrence. Guttiferone K (GUTK), a natural compound isolated from *Garcinia yunnanensis* H. H. Hu, has previously been shown to selectively eliminate QCCs. The underlying mechanism remains unclear. This study aimed to elucidate how GUTK induced death of QCCs and to evaluate its potential as a therapeutic agent for preventing tumor recurrence.

Method Quiescent prostate cancer cell models were established by serum deprivation and contact inhibition. Cell death, apoptosis and mitochondrial membrane potential were evaluated by flow cytometry, JC-1 staining and Western blotting. Proteomic analysis was performed to identify candidate proteins involved in the response to GUTK. The functional role of mitochondrial ribosomal protein S34 (MRPS34) was assessed using lentiviral knockdown and overexpression models in vitro and in a quiescent PC-3 xenograft model. Autophagy and mitophagy were examined using pharmacological modulators, mitochondrial fractionation, Western blotting, immunofluorescence and mito-Keima assays. The anti-recurrence efficacy of GUTK was further evaluated in a docetaxel-treated DU145 xenograft model.

Results GUTK induced mitochondrial membrane depolarization and apoptosis in quiescent prostate cancer cells in a time- and dose-dependent manner, accompanied by increased expression levels of cleaved caspase-9, cleaved caspase-3 and cleaved PARP, as well as reduced Bcl-2 expression. Proteomic analysis identified MRPS34 as a markedly downregulated protein following GUTK treatment. Lower MRPS34 expression was associated with improved patient survival and a reduced risk of recurrence. MRPS34 knockdown enhanced GUTK-induced mitochondrial dysfunction and apoptosis in QCCs, whereas MRPS34 overexpression attenuated these effects. Consistently, MRPS34 knockdown suppressed tumor regrowth in the quiescent PC-3 xenograft model. Mechanistically, GUTK activated autophagy, as indicated by reduced p62 expression. Autophagy inhibitor chloroquine attenuated GUTK-induced MRPS34 downregulation and apoptosis, whereas autophagy inducer Torin-1 enhanced these effects. GUTK also promoted PINK1/Parkin-mediated mitophagy, as evidenced by increased mitochondrial PINK1 and Parkin levels, reduced mitochondrial MRPS34 abundance, decreased expression of MFN1, MFN2 and TOM20, increased mitochondria-lysosome colocalization and enhanced mito-Keima fluorescence signals. Pharmacological inhibition of mitophagy with AC220 attenuated these effects. In the docetaxel-treated DU145 xenograft model, GUTK markedly delayed tumor relapse and significantly prolonged overall survival.

Conclusion GUTK induces apoptosis in quiescent prostate cancer cells by promoting PINK1/Parkin-mediated mitophagy and the associated downregulation of MRPS34. In addition, GUTK suppresses post-chemotherapy tumor recurrence and prolongs survival in vivo. These findings identify mitophagy-associated MRPS34 depletion as a potential vulnerability of QCCs and support the further development of GUTK as a therapeutic strategy for preventing prostate cancer relapse.

References

1. Xi Z, Yao M, Li Y, et al. Guttiferone K impedes cell cycle re-entry of quiescent prostate cancer cells via stabilization of FBXW7 and subsequent c-MYC degradation. *Cell Death Dis.* 2016;7(6):e2252.

Funding

This work was supported by Shanghai Science and Technology Innovation Action Plan (NO. 22YF1445100) and National Natural Science Foundation of China (NO. 81803571, 82204437).

Multi-Target Therapeutic Effects of *Coptidis Rhizoma* in Obesity, Dyslipidemia, and Type 2 Diabetes: Translational evidence from, In Silico, In Vivo, and Meta-Analysis studies

黄连对肥胖、血脂异常及 2 型糖尿病的多靶点治疗作用：
基于计算机模拟、体内实验与荟萃分析的转化医学证据

Chae-Yeon Kang^{1,2}, Yeon-Joo Yoo^{1,2}, Ji-Han Kim¹, Seung-Hoon Yoo¹, Hyeon-Joo Kim¹, Oh-Jun Kwon^{1,2}, Ji-Won Noh^{1,2}, Min-Seong Lee^{1,2}, Byung-Cheol Lee^{1,2}

¹Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, 26, Kyungheedaero, Dongdaemun-gu, Seoul 02447, Republic of Korea; ²Department of Nephrology & Endocrinology, Kyung Hee University Korean Medicine Hospital, Kyung Hee Medical Center, 23 Kyungheedaero, Dongdaemun-gu, Seoul 02447, Republic of Korea

Introduction Obesity, dyslipidemia, and type 2 diabetes mellitus form an interconnected pathogenic cluster driven by adipose inflammation, disrupted lipid homeostasis, and systemic insulin resistance. Although *Coptidis Rhizoma* (CR) and its primary constituent, berberine, have emerged as promising metabolic regulators^{1, 2} and their cellular mechanisms in obesity-induced inflammation have been previously characterized³, evaluating their comprehensive therapeutic value demands an integrated approach bridging clinical reality with biological plausibility. To address the translational gap of traditional reviews, this study establishes a robust, three-stage framework vertically integrating *in silico* network pharmacology, *in vivo* experimental validation, and a systematic meta-analysis to investigate the multi-target therapeutic effects of CR in metabolic dysfunction.

Methods To achieve this, a comprehensive three-stage methodology was applied. First, an *in silico* network pharmacology approach was applied to identify overlapping targets between berberine and disease-related genes, followed by pathway enrichment and molecular docking analyses. Second, these computational predictions were validated through an *in vivo* experiment using C57BL/6 mice fed a 60% high-fat diet (HFD) for 16 weeks, with oral administration of CR extract (200 or 400 mg/kg/day) or metformin (200 mg/kg/day) during the final 10 weeks. Third, to scale these mechanistic findings into clinical relevance, a systematic review and meta-analysis of 19 randomized controlled trials (RCTs) evaluating CR-containing formulations was conducted.

Results The integrated results systematically demonstrated the multi-target efficacy of CR. Mechanistically, *in silico* network pharmacology identified major common hub targets—including *PIK3CA*, *HTR6*, *JA K2*, *MAOA*, and *PARP1*—directly associated with lipid metabolism, inflammatory signaling, and PI3K-Akt/MAPK cascades, confirmed by stable molecular docking binding affinities. Experimentally, *in vivo* validation proved that CR systematically alleviated HFD-induced dysfunction by suppressing obesity-related phenotypes (body weight, liver weight, fat pad mass), optimizing dyslipidemia (serum cholesterol, free fatty acids), and attenuating glycemic dysfunction (OGTT areas under the curve, fasting insulin, HOMA-IR). Crucially, CR suppressed adipose tissue macrophage (ATM) infiltration, decreasing inflammatory CD11c⁺ M1 ATMs while increasing anti-inflammatory CD206⁺ M2 ATMs, alongside downregulating inflammatory and chemokine genes (TNF- α , F4/80, CCL2, CCL4, CCL5). Clinically, the meta-analysis validated these findings, demonstrating that CR significantly improved key metabolic parameters, highlighted by marked reductions in primary outcomes—body weight, LDL-C, and HbA1c—alongside broader optimizations in overall lipid profiles and glycemic control.

Conclusion This study provides a definitive translational trajectory that moves from virtual screening to preclinical validation, and ultimately to clinical verification. By uncovering the precise molecular rationale of berberine and validating its systemic anti-inflammatory and metabolic efficacy across organismal and clinical levels, this integrated framework firmly establishes the systems-level therapeutic potential of CR. These findings offer robust scientific justification for the clinical application of CR and berberine as multi-target interventions for complex metabolic disorders.

Acknowledgement This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: RS-2025-02219175).

References

1. Zhang, Y.; Li, X.; Zou, D.; Liu, W.; Yang, J.; Zhu, N.; Huo, L.; Wang, M.; Hong, J.; Wu, P.; et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. *J Clin Endocrinol Metab* 2008, 93, 2559-2565, doi:10.1210/jc.2007-2404.
2. Ye, Y.; Liu, X.; Wu, N.; Han, Y.; Wang, J.; Yu, Y.; Chen, Q. Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. *Front Pharmacol* 2021, 12, 653887, doi:10.3389/fphar.2021.653887.
3. Noh, J.W.; Jun, M.S.; Yang, H.K.; Lee, B.C. Cellular and Molecular Mechanisms and Effects of Berberine on Obesity-Induced Inflammation. *Biomedicines* 2022, 10, doi:10.3390/biomedicines10071739.

***Hericium erinaceus* Mycelium Polysaccharide Alleviates Spontaneous Ulcerative Colitis
in Monkeys by Enhancing IPA-Mediated Macrophage Efferocytosis
via Lysosomal Regulation**

猴头菇菌丝体多糖调控 IPA-巨噬细胞溶酶体-胞葬轴改善溃疡性结肠炎

Zhengyu Ren and Jiahong Lu*

Institute of Chinese Medical Sciences, University of Macau.

The lack of effective therapies for inflammatory bowel disease (IBD) represents a major unmet clinical need. Most preclinical models rely on chemically induced acute colitis with limited human relevance. Here we utilized a spontaneous ulcerative colitis (UC) monkey model that closely recapitulates human disease, characterized by insufficient macrophage efferocytosis and typical UC-like histological changes in the colon. Serum metabolomics revealed a marked decrease of the gut microbial metabolite indole-3-propionic acid (IPA) in UC monkeys compared to healthy controls, and metagenomics confirmed that IPA-producing *Limosilactobacillus*__t__SGB7095 was also reduced. Remarkably, oral administration of *Herichium erinaceus* mycelium polysaccharide (HMP), a traditional Chinese medicinal fungus-derived polysaccharide, significantly restored IPA levels and the abundance of IPA-producing bacteria.

Mechanistically, although IPA has been previously reported to show therapeutic efficacy via T-cell modulation, our findings challenge this established mechanism. We observed that IPA retained its protective effect in Rag1 knockout (KO) mice, ruling out T-cell dependence. More importantly, IPA efficacy was abolished upon macrophage depletion, identifying macrophages as indispensable. In vitro efferocytosis assays demonstrated that IPA robustly enhanced macrophage efferocytosis by specifically regulating lysosomal function. This finding was further validated in vivo using an efferocytosis-deficient MerTK KO mouse model. Consequently, IPA treatment increased the efferocytosis-driven production of pro-resolution cytokines IL-10 and TGF- β . HMP-conditioned medium (enriched in IPA) recapitulated the efferocytosis-enhancing effect.

Taken together, this study delineates a novel lysosomal-dependent pathway by which a TCM-derived polysaccharide (HMP) boosts endogenous IPA to restore macrophage efferocytosis and intestinal homeostasis in a spontaneous UC model with high human relevance. Our findings lay the groundwork for pioneering therapies targeting the microbiota–IPA–efferocytosis axis in IBD.

Acknowledgement This study was supported by the following grants: National Natural Science Foundation of China (No. 82271455) awarded to Jia-Hong Lu and National Natural Science Foundation of China (No. 825B200100) awarded to Zhengyu Ren.

Exosome-Enabled Oridonin-Based Bridged PROTACs for Targeted Androgen Receptor Degradation in Androgenetic Alopecia

基于外泌体递送的冬凌草甲素桥联 PROTAC 用于雄激素受体靶向降解治疗雄激素脱发

FC Liang¹, ZN Zhang², C Liang^{2#} and AP Lyu^{1#}

¹*School of Chinese Medicine, Hong Kong Baptist University, Hong Kong;* ²*Department of Systems Biology, School of Life Sciences, Southern University of Science and Technology*

Androgenetic alopecia (AGA) is the most prevalent form of hair loss, yet current therapies remain limited by variable efficacy and poor long-term outcomes¹. Aberrant androgen receptor (AR) signaling in dermal papilla cells drives hair follicle miniaturization and hair cycle dysregulation, but conventional AR-targeted strategies mainly inhibit AR activity rather than eliminate AR protein². Proteolysis-targeting chimeras (PROTACs) represent an emerging strategy for targeted protein degradation, but their unfavorable pharmacokinetic properties and limited bioavailability hinder clinical translation³. Herein, we developed a Chinese medicine-driven, oridonin-derived bridged PROTAC platform and combined it with a mesenchymal stem cell-derived exosome (MSC-Exo) delivery system for targeted AR protein degradation^{4,5}. Through rational molecular design and structure-activity relationship analysis, we established a focused library of oridonin-derived bridged PROTACs and identified OAT-01 as the lead candidate with the most potent AR-degrading activity. OAT-01 was subsequently loaded into MSC-Exo to generate the nanotherapeutic formulation EXO@TAC. EXO@TAC exhibited efficient cellular uptake, sustained release, and prolonged AR degradation. It promoted human dermal papilla cell proliferation, suppressed apoptosis, and restored Wnt/ β -catenin signaling under androgenic stress. In the AGA mouse model, EXO@TAC enhanced hair regeneration, improved follicular architecture, and remodeled the perifollicular microenvironment with a favorable biosafety profile. By integrating traditional Chinese medicine-derived natural products with targeted protein degradation technology, this study provides a novel and mechanistically distinct therapeutic strategy for AGA, with potential translational value for improving long-term disease management and reducing the psychosocial burden associated with hair loss.

Acknowledgement We would like to acknowledge the assistance of SUSTech Core Research Facilities. This work is supported by the National Key R&D Program of China (2024YFC3506200 and 2024YFC3506205), the National Natural Science Foundation of China (82472394), and the Hong Kong General Research Fund (12102722, 12104825, and 12106424).

References:

- 1.Liu, Y, *et al.* *Androgenetic Alopecia. Nat Rev Dis Primers*, 2025, 11 (1), 73.
- 2.Mao, X, *et al.* *Discovery of a Novel Non-Invasive AR PROTAC Degradar for the Topical Treatment of Androgenetic Alopecia. J. Med. Chem*, 2024, 67 (24), 22218–22244.
- 3.Li, J, *et al.* *Targeted Protein Degradation in Cancers: Orthodox PROTACs and Beyond. The Innovation*, 2023, 4 (3), 100413.
- 4.Huang, J, *et al.* *Discovery of a Natural Ent-Kaurene Diterpenoid Oridonin as an E3 Ligase Recruiter for PROTACs. J. Am. Chem. Soc*, 2025, 147 (2), 1920–1937.
- 5.Feng, Z, *et al.* *Design, Synthesis, and Evaluation of Nucleolin-Bridged, MDM2-Recruiting IRAK4 Degraders for the Treatment of Autoimmune Diseases. J. Med. Chem*, 2026, 69 (4), 4855–4872.

Cytochrome P450 Interactions Between Cardioprotective Chinese Herbal Medicines and Antiretroviral Drugs: A Systematic Review of In Vivo Evidence

心血管保护作用中药与抗逆转录病毒药物的细胞色素 P450 相互作用： 体内研究的系统综述

Wan-Jung Cheng¹, Anthony Jaworowski^{1,2,3}, Janine M. Trevillyan^{4,5}, Anna C. Hearps^{2,3,5}, Iris Zhou¹, Charlie C. Xue¹ and Anthony L. Zhang¹

¹ School of Health and Biomedical Sciences, Royal Melbourne Institute of Technology (RMIT) University, Bundoora, VIC, Australia; ² Life Sciences Discipline, Burnet Institute, Melbourne, VIC, Australia; ³ Department of Infectious Diseases, Monash University and the Alfred Hospital, Melbourne, VIC, Australia; ⁴ Department of Infectious Diseases & Immunology; Clinical Virology and HIV Services, Austin Health, Melbourne, VIC, Australia; ⁵ Department of Infectious Diseases, Peter Doherty Institute of Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia

Introduction With increasing effectiveness of antiretroviral therapy (ART), people living with HIV are experiencing longer life expectancy alongside a growing burden of comorbidities, particularly cardiovascular disease^{1,2}. Chinese herbal medicine is frequently co-administered in this population; however, potential herb–drug interactions remain a clinical concern due to modulation of cytochrome P450 (CYP450) enzymes, particularly for drugs with narrow therapeutic indices.

Methods A systematic review of in vivo studies was conducted using PubMed, Embase, Scopus, and CNKI up to March 2025. Studies investigating aqueous extracts of six commonly used Chinese medicinal herbs (*Salvia miltiorrhiza*, *Ligusticum chuanxiong*, *Glycyrrhiza uralensis*, *Angelica sinensis*, *Astragalus membranaceus*, and *Atractylodes macrocephala*) were included. Outcomes included CYP450 enzyme activity, protein expression, mRNA expression, and pharmacokinetic parameters. Study quality was assessed using the SYRCLE risk of bias tool. A structured EMS-CI framework was applied to quantify the direction and consistency of CYP450 modulation across heterogeneous datasets.

Results Three consistent CYP450 modulation patterns were identified across studies: neutral, inhibitory-dominant, and induction-dominant profiles. *Salvia miltiorrhiza* demonstrated predominantly neutral modulation across major CYP isoforms. *Ligusticum chuanxiong* showed consistent inhibitory effects, particularly on CYP2B6 and CYP3A4. *Glycyrrhiza uralensis* demonstrated induction-dominant effects. *Angelica sinensis* exhibited mixed modulation across CYP isoforms. *Astragalus membranaceus* and *Atractylodes macrocephala* showed heterogeneous or limited evidence profiles. CYP3A4 and CYP2B6 were identified as the most consistently affected enzymes across all included studies.

Discussion A substantial proportion of antiretroviral agents, including protease inhibitors, boosted regimens, and selected non-nucleoside reverse transcriptase inhibitors, are metabolized via CYP3A4 and CYP2B6 pathways, whereas nucleoside reverse transcriptase inhibitors and most integrase strand transfer inhibitors demonstrate limited CYP450 dependence. The findings demonstrate that herb–drug interactions are not uniform but follow identifiable pharmacological modulation patterns. Application of the EMS-CI framework enables structured comparison across heterogeneous in vivo evidence and supports the development of a pathway-based risk stratification model for predicting herb–drug interactions. This framework may assist in guiding safer co-administration strategies, particularly for drugs with narrow therapeutic indices or high CYP metabolic dependency.

Conclusion Chinese medicinal herbs demonstrate distinct and predictable CYP450 modulation patterns. A pathway-oriented risk stratification approach may improve the safety and precision of integrating Chinese herbal medicine with antiretroviral therapy in clinical practice.

Acknowledgement The authors would like to express their sincere gratitude to their supervisory team for their invaluable guidance, critical feedback, and continuous support throughout this study. This work was supported by a PhD Scholarship from RMIT University and a grant from the OpalGate Foundation, Australia.

References

1. Marcus, J. L., et al. Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016. *JAMA Netw Open*, 2020. 3(6), e207954.
2. Ruamtawee, W., et al. Prevalence and risk factors of cardiovascular disease among people living with HIV in the Asia-Pacific region: a systematic review. *BMC Public Health*, 2023. 23(1), 477.

Herb–Drug Interactions in Integrative Care: From Active Surveillance to Research, Clinical Practice, and Governance

整合医学中的草药-药物相互作用：从主动监测、研究、临床实践到治理

CYJ Ng, and LLD Zhong

School of Biological Sciences, Nanyang Technological University

The growing global use of herbal medicines alongside conventional Western medicines (WM) has created an urgent need to better understand, detect, and prevent herb–drug interaction-related adverse events. This presentation draws on two of our published studies examining herbal medicine safety from complementary perspectives. The first is a multi-center active surveillance study conducted across Chinese Medicine clinics in Singapore, which found that concurrent Chinese Herbal Medicine (CHM) and WM consumption was common, occurring in 62.65% of screened patients¹. Patients using both CHM and WM were also more likely to report adverse events compared to those using CHM alone, highlighting the importance of structured medication history-taking, active adverse-event screening, and causality assessment in clinical practice. The second paper then examines immediate hypersensitivity reactions to herbal medicines, reviewing IgE-mediated and non-IgE-mediated mechanisms, potential triggers, diagnostic approaches, and regulatory responses². Collectively, these studies show that herb–drug interactions are not only a pharmacological issue, but also a broader clinical and public health challenge. Hence, this presentation will discuss how active surveillance, clinician awareness, pharmacovigilance, and stronger regulation can support safer and evidence-based integration of herbal medicines into modern clinical practice.

References

- 1.Ng, C.Y.J., Zhao, Y., Wang, N. et al (2024). A multi-center cross-sectional study of Chinese Herbal Medicine-Drug adverse reactions using active surveillance in Singapore’s Traditional Chinese Medicine clinics. *Chin Med* 19, 44.
- 2.Ng, C.Y.J., Zhong, L.L., & Thong, B.Y.H. (2026). Immediate hypersensitivity to herbal medicine: from diagnosis to policies. *Current Opinion in Allergy and Clinical Immunology*, 10-1097.

Gastroprotective Effects of Da Khoi Cot, A Traditional Vietnamese Polyherbal Decoction, Against Indomethacin-Induced Gastric Ulcer in Wistar rats

越南传统复方 Da Khoi Cot 对吲哚美辛诱导的 Wistar 大鼠胃溃疡的胃保护作用

Tran Thi Hong Ngai¹, Kieu Hoang Yen^{1,2}

¹Vietnam University of Traditional Medicine - Hanoi City; ²Vinh City General Hospital - Nghe An Province

The effective management of gastric ulcers, particularly those induced by non-steroidal anti-inflammatory drugs (NSAIDs), remains challenging due to the adverse effects and relapse associated with conventional therapies. Da Khoi Cot (DKC), a Vietnamese traditional decoction composed of six medicinal herbs, has been used for gastrointestinal disorders, but its efficacy has not been scientifically validated. This study evaluated the gastroprotective effects of DKC in an indomethacin-induced gastric ulcer model in rats. Wistar rats were pretreated orally for 7 days with either DKC (24 or 48 mL/kg/day) or misoprostol (50 µg/kg/day). Gastric ulcers were induced by indomethacin (40 mg/kg). Ulcer severity was assessed macroscopically and histopathologically. MDA, GSH in gastric tissue, TNF-α in serum, as well as AST, ALT, creatinine, and urea levels, were evaluated. DKC at 48 mL/kg/day significantly reduced the ulcer index, and both doses significantly reduced the number of gastric lesions compared to the ulcer control group ($p < 0.05$). Histopathological analysis demonstrated significant improvements in mucosal integrity, with reduced inflammation and hemorrhage. The decoction also produced a marked antioxidant effect, significantly decreasing gastric MDA and increasing GSH levels ($p < 0.05$ - 0.001). DKC pretreatment also considerably suppressed the indomethacin-induced rise in serum TNF-α ($p < 0.01$). No significant alterations in hepatic or renal function markers were observed. DKC exerts significant gastroprotective effects against indomethacin-induced gastric ulceration while maintaining a favorable safety profile. These results provide the first preclinical evidence supporting DKC's potential as an adjunctive therapy for NSAID-associated gastric ulcers.

Acknowledgement We would like to express our sincere gratitude to Vietnam University of Traditional Medicine and Vinh City General Hospital for providing an excellent academic environment and research facilities.

References

1. Hao W, Zheng C, Wang Z & Ma, H. Global burden and risk factors of peptic ulcer disease between 1990 and 2021: An analysis from the global burden of disease study 2021. *PLOS One*. 2025;20(7):e0325821. <https://doi.org/10.1371/journal.pone.0325821>.
2. Xie X, Ren K, Zhou Z, Dang C, Zhang H. The global, regional and national burden of peptic ulcer disease from 1990 to 2019: a population-based study. *BMC Gastroenterol*. 2022;22(1):58. <https://doi.org/10.1186/s12876-022-02130-2>.
3. Arshad SA, Murphy P, Gould JC. Management of Perforated Peptic Ulcer: A Review. *JAMA Surg*. 2025;160(4):450-454. <https://doi.org/10.1001/jamasurg.2024.6724>.
4. Abbasi-Kangevari M, Ahmadi N, Fattahi N, Rezaei N, Malekpour MR, Ghamari, SH, Moghaddam SS, Azadnajafabad S, Esfahani Z, Kolahi AA, Roshani S, Rezazadeh-Khadem S, Gorgani F, Naleini SN, Naderimagham S, Larijani B, Farzadfar F. Quality of care of peptic ulcer disease worldwide: A systematic analysis for the global burden of disease study 1990–2019. *PLoS ONE*. 2022;17(8):e0271284. <https://doi.org/10.1371/journal.pone.0271284>.
5. Lau JY, Sung J, Hill C, Henderson C, Howden CW, Metz DC. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. *Digestion*. 2011;84(2):102–113. <https://doi.org/10.1159/000323958>.
6. Lanis A, Chan FKL. Peptic ulcer disease. *Lancet Lond Engl*. 2017;390(10094):613–624. [https://doi.org/10.1016/S0140-6736\(16\)32404-7](https://doi.org/10.1016/S0140-6736(16)32404-7).

Screening and Characterization of a Novel Skeletal Muscle-Targeting Aptamer for Precise Delivery of Triptolide in Traditional Chinese Medicine Therapy of Muscle Inflammation

新型骨骼肌靶向适配体的筛选与鉴定，及其在中医药治疗肌肉炎症中
精准递送雷公藤甲素的应用

Xiaofang LI, Jintao XU, Yihao ZHANG, Hang LUO, Shanshan YAO, Ning Zhang, Bao-Ting ZHANG*, Zong-Kang ZHANG*

School of Chinese Medicine, The Chinese University of Hong Kong

Skeletal muscle is one of the largest organs in the body and plays critical roles in mechanical activity and metabolism. Chronic myopathies and acute muscle inflammation impose substantial clinical and economic burdens. Although traditional Chinese medicine (TCM) active ingredients, such as triptolide derived from *Tripterygium wilfordii*, exhibit potent anti-inflammatory and immunomodulatory effects on muscle disorders, their clinical application is severely limited by systemic toxicity, non-specific distribution, and insufficient accumulation in skeletal muscle tissues, resulting in suboptimal therapeutic efficacy and dose-dependent adverse effects. These challenges highlight the urgent need for skeletal muscle-specific drug delivery systems to improve the precision and safety of TCM-based therapies.

Aptamers are artificial, short, single-stranded nucleic acids, with unique secondary structures that can recognize and bind to targets. The high specificity, low immunogenicity, and cost-effective synthesis of aptamers make them ideal candidates for skeletal muscle-targeted delivery. In our study, a skeletal muscle-specific aptamer S77 was identified through 14 rounds of cell-SELEX (systematic evolution of ligands by exponential enrichment) against C2C12 myoblasts. After optimization, S77 exhibited a K_d value of 81.54 nM with low cytotoxicity. It effectively bound and internalized into mouse satellite cells, myoblasts, and myotubes.

By integrating S77 with tetrahedral DNA nanostructures (TDNs) as a nanocarrier to load triptolide, the S77-TDN-triptolide system was tested in an LPS-induced acute skeletal muscle inflammation mouse model. Compared with non-targeted formulations, this delivery system significantly decreased the levels of pro-inflammatory cytokines TNF- α and IL-6, attenuated the decline in forelimb grip strength, reduced muscle histopathological damage, and accelerated tissue recovery.

This study successfully developed a novel skeletal muscle-targeting aptamer S77 with high affinity and specificity. By combining it with TDN nanotechnology for precise delivery of triptolide, we provide an effective strategy to overcome the limitations of current TCM treatments for muscle disorders, offering a promising platform for safe and efficient precision therapy with strong potential for clinical translation.

Acknowledgement This study was supported by Hong Kong General Research Fund (14103121), the National Natural Science Foundation of China (82372359), Hong Kong Pneumoconiosis Compensation Fund Board Research Fund (2023RS06).

References:

1. Li X, Xu J, Yao S, Zhang N, Zhang B, Zhang Z. Targeting Drug Delivery System to Skeletal Muscles: A Comprehensive Review of Different Approaches. *J cachexia sarcopenia muscle* 2025;16:e13691.
2. Zhu G, Chen X. Aptamer-based targeted therapy. *Advanced Drug Delivery Reviews* 2022;164:75–86.
3. Xi C, Peng S, Wu Z, Zhou Q, Zhou J. Toxicity of triptolide and the molecular mechanisms involved. *Biomedicine & Pharmacotherapy* 2017;90:531–41.

Pulsatilla Decoction Granules Ameliorate Ulcerative Colitis by Inhibiting Ferroptosis through Activation of the CTCF–VDR–GPX4 Pathway via the Gut Microbiota–C15:0 Metabolic Axis
白头翁汤配方颗粒通过调控“肠道菌群–C15:0”代谢轴激活 CTCF–VDR–GPX4 通路抑制铁死亡改善溃疡性结肠炎

FeiYang LIU, XiaoQi Huang, XueBao Zheng

School of Chinese Medicine, Guangzhou University of Chinese Medicine

Background Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease with an unclear etiology. Baitouweng Decoction (BTD) has demonstrated definitive therapeutic efficacy in UC. Its granule formulation, Pulsatilla Decoction Granules (PDG), offers advantages in convenient administration, high chemical consistency with standard decoction, and bioequivalence. Accumulating evidence highlights the pivotal role of the gut microbiota and their metabolites in the pathogenesis and resolution of UC¹. Our preliminary research identified the lipid metabolism pathway as a key regulatory axis in BTD-mediated UC treatment, with pentadecanoic acid (C15:0) being the most significantly altered differential metabolite. C15:0 can be synthesized by gut microbiota and may exert protective effects by inhibiting ferroptosis²; however, its precise molecular targets and regulatory mechanisms remain elusive.

Objective This study aims to investigate whether PDG ameliorates UC by modulating the gut microbiota and its metabolite C15:0 to inhibit ferroptosis, and to elucidate the downstream molecular target and regulatory mechanism.

Methods A dextran sulfate sodium (DSS)-induced UC mouse model was established to evaluate the therapeutic effects of PDG. Metagenomic sequencing and gas chromatography-mass spectrometry (GC-MS) were performed to analyze PDG-mediated alterations in key gut microbiota and C15:0 levels. Antibiotic cocktail (ABX) intervention and fecal microbiota transplantation (FMT) were employed to validate the microbiota-dependent action of PDG. The protective effects of *Bacteroides acidifaciens* (*B. acidifaciens*), *Akkermansia muciniphila* (*A. muciniphila*), and C15:0 on UC were further assessed, along with the C15:0-producing capacity of these bacterial strains. An erastin-induced ferroptosis model was used to verify the regulatory effect of C15:0 on ferroptosis. Integrative bioinformatics and transcriptomic analyses identified the vitamin D receptor (VDR) as a key target gene, with CTCF predicted as its transcription factor. The functional linkage between CTCF and VDR was established by siRNA-mediated knockdown in NCM460 cells. Efficacy validation was performed in NCM460 human normal colonic epithelial cells using Western blotting (WB), quantitative real-time PCR (qRT-PCR), and immunofluorescence.

Results PDG significantly alleviated DSS-induced colonic inflammation, as evidenced by improved disease activity index (DAI), reduced histopathological damage, and restored intestinal barrier function. Metagenomic sequencing identified *B. acidifaciens* and *A. muciniphila* as the core gut microbiota modulated by PDG. GC-MS analysis revealed that PDG treatment significantly increased colonic C15:0 levels, and both bacterial strains possessed the capacity to synthesize C15:0. C15:0 effectively suppressed the release of pro-inflammatory cytokines and inhibited ferroptosis both in vivo and in vitro. VDR was identified and validated as the key target gene, and CTCF was found to specifically bind to the VDR promoter region. Notably, C15:0 treatment significantly upregulated the expression of CTCF, VDR, and its downstream target glutathione peroxidase 4 (GPX4).

Conclusion PDG alleviates UC by enriching *B. acidifaciens* and *A. muciniphila*, thereby promoting the synthesis of their metabolite C15:0. This metabolite, in turn, activates the CTCF–VDR–GPX4 signaling axis, inhibits ferroptosis in colonic epithelial cells, and restores intestinal barrier integrity.

Acknowledgement This work was supported by the Enterprise Joint Fund General Project of the grant 2023A1515220035.

References:

1. Ning L, Zhou YL, Sun H, et al. Microbiome and metabolome features in inflammatory bowel disease via multi-omics integration analyses across cohorts[J]. *Nature Communications*, 2023, 14(1): 7135.
2. Yang, Y, Fu, Y, Wu, C. Gut microbe-derived pentadecanoic acid could represent a novel health-promoter via multiple pathways. *Food Funct.* 2025; 16 (12): 4636-4653.

Food as Medicine: Traditional Fermented Foods as Dietary Interventions for Neuroinflammation and Healthy Ageing

药食同源：传统发酵食品作为针对神经炎症与健康衰老的膳食干预措施

Desanka Milanovic, Milica Prvulovic, Andjela Vukojevic, Smilaj Pracer,
Aleksandra Mladenovic

Institute for Biological Research "Siniša Stanković" - National Institute of Republic of Serbia, University of Belgrade, Serbia

Background Traditional medical systems have long recognised the therapeutic role of food in maintaining health and preventing disease. Contemporary biomedical research increasingly supports this concept, particularly regarding fermented foods, which contain bioactive metabolites and beneficial microorganisms capable of modulating immune and metabolic functions. Chronic inflammation/neuroinflammation is major drivers of ageing, frailty, cognitive decline, and numerous chronic disorders, underscoring the need for safe, preventive, and sustainable interventions.

Methods We investigated the biological effects of two traditional fermented food products. The first product (FF1), a naturally fermented fruit-based preparation, was evaluated in murine models of lipopolysaccharide (LPS)-induced inflammation and ageing, as well as in a pilot human intervention study. Behavioural, cognitive, and frailty-related outcomes were assessed following prolonged consumption. In parallel, sauerkraut brine (SB), a traditional fermented cabbage product rich in lactic acid bacteria, was examined in acute and repeated models of LPS-induced neuroinflammation in mice, assessing inflammatory, oxidative stress, and behavioural parameters.

Results FF1 significantly attenuated LPS-induced inflammation and improved behavioural and cognitive performance in aged mice. Moreover, three months of FF1 consumption reduced frailty scores in human participants, suggesting beneficial effects on healthspan. SB markedly reduced neuroinflammatory responses, decreasing the expression of pro-inflammatory cytokines in the prefrontal cortex following LPS challenge and preserving antioxidant defences during repeated inflammatory exposure. Behavioural analyses further suggested attenuation of anxiety-like behaviour in SB-treated animals.

Conclusions Two traditional fermented food products demonstrated benefits on systemic inflammation, neuroinflammation, oxidative stress, cognition, behaviour, and frailty. These findings provide experimental and preliminary clinical evidence supporting the concept of “food as medicine” and highlight fermented foods as accessible, culturally rooted, and non-pharmacological interventions for promoting resilience and healthy ageing. The results further illustrate how traditional dietary practices can be integrated with modern evidence-based approaches to support long-term health and disease prevention.

ABSTRACT INDEX

NO.	Presenter	Title
B-01	YANG Jinzhao <i>City University of Hong Kong</i>	SMAD4-LGALS9 signaling promotes atherosclerosis progression through endothelial dysfunction
B-02	YUAN Wenli <i>The Chinese University of Hong Kong</i>	AC01 Enhancing Lymphatic Function and Reducing Inflammation and Fibrosis in Experimental Models of Lymphatic Dysfunction
B-03	LIANG Yuting <i>The Chinese University of Hong Kong</i>	A TCM Herbal Formula Combined with Mechanical Vibration for Managing Sarcopenia
B-04	QIN Zehui <i>The Chinese University of Hong Kong</i>	Bruceine A induced cuproptosis is a novel strategy to enhance the efficacy of gemcitabine in the treatment of pancreatic cancer
B-05	LI Xinyi <i>Guangzhou University of Chinese Medicine</i>	Alkaloids of <i>Phellodendri Chinensis</i> Cortex Exerts Uric Acid-Independent Renoprotection in Uric Acid Nephropathy via the PFKFB3-Glycolysis-Macrophage Axis
B-06	LIU Kangqi <i>Guangzhou University of Chinese Medicine</i>	Acetylursolic Acid Attenuates Ferroptosis in Myocardial Ischemia/Reperfusion Injury by Inhibiting STING-Mediated Autophagic Degradation of GPX4
B-07	JIANG Weihao <i>Guangzhou University of Chinese Medicine</i>	Taohong Siwu Decoction Attenuates Post-Myocardial Infarction Myocardial Fibrosis by Suppressing the PFKP-Glycolysis Axis
B-08	Li Ziwen <i>Guangzhou University of Chinese Medicine</i>	D2R-PI3K-OCT2 axis underlies the adipocyte uptake of tetrahydroberberine and its therapeutic effect in obesity
B-09	HUANG Jinhao <i>Guangzhou University of Chinese Medicine</i>	Elucidating the mechanism of Coptidis Rhizoma bioactive constituent in ameliorating UC comorbid with anxiety/depression through regulating CXCL9 expression via MDC1 non-canonical transcriptional elongation
B-10	Li Zikang <i>Guangzhou University of Chinese Medicine</i>	Cyclo(Gly-Tyr) alleviates hypercholesterolemia via modulating gut microbiota: critical roles and mechanisms of <i>Bacteroides</i> and <i>Akkermansia</i>
B-11	WANG Juan <i>Guangzhou University of Chinese Medicine</i>	Brucea javanica Oil Emulsion Ameliorates Ulcerative Colitis via DNASE2- Mediated Suppression of Cytosolic DNA-Sensing Signaling: Mechanistic Insights and Functional Contribution of Bruceine D
B-12	HUANG Weimu <i>Guangzhou University of Chinese Medicine</i>	Mechanistic Study of Brusatol Targeting Sucla2 to Regulate Macrophage Polarization for the Treatment of Ulcerative Colitis
B-13	WENG Xiaoya <i>Guangzhou University of Chinese Medicine</i>	Gut–liver crosstalk mechanism underlying the lipid-lowering enhancement of debitterized Citri Grandis Exocarpium: the pivotal role of the <i>Akkermansia muciniphila</i>–indole-3-carboxaldehyde–FXR axis
B-14	LI Tianhui <i>The Hong Kong Polytechnic University</i>	Pomegranate ellagitannin improves cholesterol metabolism through <i>Akkermansia</i>-associated bile acid remodeling
B-15	LEE Pui Kei <i>The Hong Kong Polytechnic University</i>	Investigating Chinese Sweet Tea Leaf Extract as a “Sweet” Remedy for Obesity-Associated Metabolic Disorders
B-16	LI Yue <i>The Hong Kong Polytechnic University</i>	Buyanghuanwu decoction Reduce Fibrosis and Improve Diastolic Dysfunction
B-17	DONG Tianyu <i>The University of Hong Kong</i>	<i>In vitro</i> and <i>in vivo</i> investigations on the anti-metastasis and anti-stemness effects of a polysaccharides-rich herbal extract SOL on triple negative breast cancer
B-18	LIU Qing <i>The University of Hong Kong</i>	APPL2 Deletion Promotes Neurogenesis and Functional Recovery after Ischemic Stroke via Regulation of Mitochondrial Dynamics and Function
B-19	YU Wei <i>The University of Hong Kong</i>	<i>Andrographis paniculata</i> Suppresses Aggressive Cancer Stem Cell-Driven Ovarian Cancer Metastasis by Inhibiting SP100 Downstream of Wnt/β-Catenin Signaling
B-20	Zhang Shuo <i>The University of Hong Kong</i>	Potential effects of Chinese herbal formula SP on obesity-associated colon cancer

ABSTRACT INDEX

		through adipocytes–cancer cells interaction
B-21	DILIDAER Ajiaikebaier <i>The Hong Kong University of Science and Technology</i>	Xanthohumol Alleviates TNF- α -Induced Inflammation in IEC-6 Cells
B-22	YE Yutong <i>The Hong Kong University of Science and Technology</i>	Yu Ping Feng San Prevents the Cisplatin- and 5-Fluorouracil-Induced Multi-Drug Resistance in <i>Escherichia coli</i>
B-23	YIK Lok Pan <i>The Hong Kong University of Science and Technology</i>	Yu Ping Feng San Prevents the Anti-Cancer Drugs Induced Inflammation in Intestinal Epithelial Cells (IEC-6 Cells)
B-24	ZHU Jiayu <i>The Hong Kong University of Science and Technology</i>	Photoprotective and Anti-Inflammatory Effects of Wild Mountain Ginseng Extract Against Ultraviolet-Induced Damage in HaCaT Cells
B-25	ZHOU Chenchen <i>Hong Kong Baptist University</i>	Anti-Atopic Dermatitis Effects and Mechanisms of Action of Tetramethylpyrazine
B-26	WANG Juan <i>Hong Kong Baptist University</i>	Systematic Review of Preclinical Evidence on Antifibrotic
B-27	RidaZAINAB <i>Hong Kong Baptist University</i>	Effects of Sulfur- and Selenium-Containing Miliusane Analogues on Cellular Senescence induction in Triple-Negative Breast Cancer
B-28	WU Sixia <i>Hong Kong Baptist University</i>	Plant Lignans Target Host-Driven Viral Entry for Broad-Spectrum Antiviral Activity
B-29	LI Meng <i>Nanyang Technological University</i>	Polysaccharide-Based Treatment Strategies for Irritable Bowel Syndrome: Targeting the Gut–Brain–Microbiota Axis
B-30	LUO Shangfei <i>Shandong University of Traditional Chinese Medicine</i>	Taohe Chengqi decoction attenuates metabolic dysfunction-associated steatohepatitis by suppressing Piezo1/NLRP3 mediated macrophage inflammation
B-31	CHEN Jianle <i>Shanghai University of Traditional Chinese Medicine</i>	Multi-target Pharmacological Mechanisms and Translational Evidence of Traditional Chinese Medicine in Hair Follicle Regeneration and Alopecia Treatment: A Review
B-32	GUAN Xiaoqi <i>Shanghai University of Traditional Chinese Medicine</i>	Gut microbiota-derived butyrate mediates the cardioprotective effects of Modified Taohong Siwu Decoction via the HDAC -PPAR γ axis in macrophages
B-33	ZHANG Yongkang <i>Shanghai University of Traditional Chinese Medicine</i>	The “Ruanjian Qingmai” Formula Regulates Macrophage Lipid Metabolism and Polarization to Treat Atherosclerosis via AMPK-Dependent PPAR γ Activation
B-34	JIANG Fengru <i>Shanghai University of Traditional Chinese Medicine</i>	Shugan Decoction ameliorates colonic motility dysfunction induced by WAS in rats by inhibiting the tryptophan IDO1/AHR signaling pathway
B-35	MA Mengling <i>Shanghai University of Traditional Chinese Medicine</i>	EC alleviates HFD-induced sarcopenic obesity via Sirt3- mediated deacetylation of SOD2 at K68
B-36	QIAN Hao <i>Shanghai University of Traditional Chinese Medicine</i>	Xiao-Yao-San suppresses psychological distress-related colorectal cancer metastasis and enhances antitumor immune responses through regulating gut microbiota–bile acid axis
B-37	CHEN Yuwen <i>Shanghai University of Traditional Chinese Medicine</i>	Stachydrine hydrochloride Protects Against Doxorubicin-Induced Cardiotoxicity by Stabilizing Optic Atrophy 1 Protein and Preserving Mitochondrial Integrity
B-38	ZHENG Miyi <i>Shanghai University of Traditional Chinese Medicine</i>	Baohuoside I Alleviates Dexamethasone-Induced Muscle Atrophy by Targeting FGF21 to Attenuate DNA Damage
B-39	ZHANG Kaiyue <i>Shanghai University of Traditional Chinese Medicine</i>	Effect of Tuina on Hypothalamic Orexin-A Expression and Sleep Behavior in a Rat Model of Primary Insomnia
B-40	HE Qiyun <i>Shanghai University of</i>	Effects of 10.6 μ m Laser Moxibustion and Traditional Moxibustion on STZ-Induced Diabetic Peripheral Neuropathy in Rats Under Background Glycemic Control

ABSTRACT INDEX

	<i>Traditional Chinese Medicine</i>	
B-41	CHEG Feng <i>Shanghai University of Traditional Chinese Medicine</i>	HLPP Inhibits White Adipose Tissue Expansion and Promotes Brown Adipose Tissue Mitochondrial Thermogenesis in diet-induced Obese Mice via the DUSP4-ERK MAPK Signaling Pathway
B-42	ZAHNG Yuxiao <i>Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine</i>	Baicalein, a natural constituent of Scutellaria baicalensis, inhibits Gastric Cancer Cell Migration and Represents a novel Strategy Against Gastric Cancer Metastasis
B-43	LIN Miaoting <i>The Second Affiliated Hospital of Guangzhou Medical University</i>	Direct Inhibition of Macrophage STING Signaling by Bisdemethoxycurcumin Ameliorates Myocardial Infarction-Induced Inflammation and Cardiac Dysfunction
B-44	XIE Mengting <i>The Second Affiliated Hospital of Guangzhou Medical University</i>	Przewaquinone A inhibits neutrophil extracellular trap formation through the Piezo1/Runx1 axis to ameliorate hypertension
B-45	LIANG Miaoixian <i>The Second Affiliated Hospital of Guangzhou Medical University</i>	Ilex Pubescens Inhibits Ferroptosis post-myocardial ischemia-reperfusion injury by activating aldehyde dehydrogenase 2
B-46	YANG Lining <i>The Second Affiliated Hospital of Guangzhou Medical University</i>	Dihydrotanshinone I Activates ALDH2 to Suppress Myocardial Cell Ferroptosis Following Myocardial Infarction
B-47	LI HUA <i>The Second Affiliated Hospital of Guangzhou Medical University</i>	HDAC1 Inhibition by Albiflorin Attenuates Cardiac Fibrosis After Myocardial Infarction via Blockade of TGFβR1/Smad2/3 Pathway
B-48	JUE Xiaoyu <i>The Second Affiliated Hospital of Guangzhou Medical University</i>	Levistolide A ameliorates sepsis-induced cardiac dysfunction by inhibiting ferroptosis via the SIRT1-NRF2 pathway
B-49	LIU Kangqi <i>The Second Affiliated Hospital of Guangzhou Medical University</i>	Acetylursolic Acid Attenuates Ferroptosis in Myocardial Ischemia/Reperfusion Injury by Inhibiting STING-Mediated Autophagic Degradation of GPX4
B-50	WENG Junsong <i>The Second Affiliated Hospital of Guangzhou Medical University</i>	Taohong Siwu Decoction Attenuates Myocardial Fibrosis by Promoting Ubiquitination and Proteasomal Degradation of HDAC1
B-51	Zheng Feiyang <i>University of Macau</i>	Rosmarinic acid ameliorates endothelial dysfunction and oxidative stress in HFD/STZ-induced type 2 diabetic mice
B-52	CHANG Haoran <i>University of Macau</i>	Rosmarinic acid protects against isoproterenol-induced myocardial infarction in rats
B-53	XIAO Rufe <i>University of Macau</i>	Polysaccharides from Magnoliae Officinalis Cortex Ameliorate Ulcerative Colitis via Gut Microbiota-Mediated Restoration of Treg/Th1/Th17 Immune Homeostasis
C-01	LAM Wai Ching <i>Nanyang Technological University</i>	Acupuncture for constipation-dominant irritable bowel syndrome: a systematic review and meta-analysis
C-02	LIU Lu <i>Shanghai University of Traditional Chinese Medicine</i>	Effectiveness of 10.6μm CO2 laser acupuncture for breast cancer-related lymphedema: a randomized controlled trial
H-01	KTCHAN <i>The Chinese University of Hong Kong</i>	Composition, authentication, and ethnopharmacological rationale of Five Flowers Herbal Tea in Hong Kong
H-02	NG Yan Jie Chester <i>Nanyang Technological University</i>	Medical Food Therapy as an Emerging Anti-Aging and Regenerative Intervention
Q-01	CHAN Kam Chun <i>Hong Kong Baptist University</i>	Tryptophan sulfonate: A new chemical marker for accurate and efficient inspection of sulfur-treated herbal medicinal products
Q-02	XU Feng <i>Hubei University of Chinese Medicine</i>	AI-Assisted Microscopic Identification of Coptidis Rhizoma Powder Based on Deep Learning

ABSTRACT INDEX

P-01	LAM Ka Hei Terence <i>Hong Kong Baptist University</i>	The Design and Synthesis of Novel Nitrogen-containing Diphyllin Analogues as Anti-avian Influenza Virus Agents
P-02	ZHANG Chaowei <i>Hong Kong Baptist University</i>	<i>Kluyveromyces marxianus</i> as a Promising Biocatalyst for the Biotransformation of Resveratrol to Dihydroresveratrol
P-03	LI Hui <i>Shanghai University of Traditional Chinese Medicine</i>	Concise Synthesis of Rare Amino Acids in Bioactive Natural Cyclic Peptides
P-04	WANG Mei <i>Shenzhen University</i>	Targeted Isolation and Screening and of Anti-Renal Fibrosis Compounds from <i>Aquilaria sinensis</i>
X-01	WU Zhiming <i>City University of Hong Kong</i>	Development of a Versatile Flow Chamber for the Simulation of Multiple Hemodynamic Conditions
X-02	SEETOH Wei Song <i>Nanyang Technological University</i>	Efficacy of Traditional Chinese Medicine Herbal Formulas for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Reclassified Randomized Controlled Trials
X-03	WEI Kunchen <i>Shanghai University of Traditional Chinese Medicine</i>	Development and Comprehensive Multi-Database Validation of an Interpretable Machine Learning Model for Predicting 28-Day Mortality in ICU Patients with <i>Staphylococcus aureus</i> Bacteremia
X-04	WU Congqi <i>Shanghai University of Traditional Chinese Medicine</i>	Research Hotspots and Frontiers of Tuina and Massage Therapies for Neuropathic Pain Based on CiteSpace and VOSviewer
X-05	HUANG Congrui <i>Shanghai University of Traditional Chinese Medicine</i>	Potential Application of Single-Cell and Spatial Transcriptomics in Acupuncture Research on Asthma
X-06	LI Mengjia <i>Shanghai University of Traditional Chinese Medicine</i>	Analysis of the Current Situation of Clinical Trial Registrations of Artificial Intelligence in Traditional Chinese Medicine
X-07	GU Tianyu <i>Shanghai University of Traditional Chinese Medicine</i>	Multi-Modal Sensor Fusion for Objective Quantification and Intelligent Recognition of Acupuncture Manipulation
X-08	ZHONG Yi <i>Shanghai University of Traditional Chinese Medicine</i>	Massage Therapy Improves Cognitive Impairment in Patients with Autism Spectrum Disorder: A Systematic Review and Meta-Analysis
X-09	ZHANG Pingping <i>Shanghai University of Traditional Chinese Medicine</i>	A Pose Estimation-Based Action Similarity Assessment System for Liuzijue Qigong: Dataset Construction, Model Optimization, and Reliability Validation
X-10	LI Hui <i>Shanghai University of Traditional Chinese Medicine</i>	Integrative Transcriptomics and Machine Learning Uncover Hub Genes Governing the Oxidative Stress-Immune Inflammation Axis in COPD
X-11	WANG Xiaoqiu <i>Shanghai University of Traditional Chinese Medicine</i>	Effects of Cervical Jiaji-Point Tuina on Neuropathic Pain in Rats Following Upper Trunk Brachial Plexus Avulsion
X-12	FANG Yichen <i>Shanghai University of Traditional Chinese Medicine</i>	Analysis of Current Trends in Physical Therapy for Chronic Pelvic Pain and a Discussion on Tuina: A Visualization of Bibliometric Analysis
X-13	WANG Jingwen <i>Shanghai University of Traditional Chinese Medicine</i>	Clinical effectiveness and safety of combined acupuncture-medicine anesthesia for cesarean delivery: a systematic review and meta-analysis
X-14	NIE Yuhan <i>Shanghai University of Traditional Chinese Medicine</i>	A Quantitative System for Traditional Chinese Medicine Acupuncture Manipulation Based on MediaPipe and Sensor Fusion

For more abstracts and the full articles, please scan the QR code to view.

